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South Africa has the largest number of people living with HIV and the largest HIV 
treatment program in the world, supplying antiretroviral therapy (ART) to 66% of 
the 7.6 million people living with HIV in the country in 2019. To reach the 
remaining 34%, the already overburdened health system needs to find ways of 
attracting and retaining groups at higher risk of attrition and optimizing 
convenience for providers and patients.  We identified three examples of 
“differentiated service delivery”, an approach that adapts HIV services to patient 
and health system needs: (1) male clinics, attended and staffed exclusively by 
men, (2) youth clinics, exclusively for youth aged 12–25, offering flexible hours 
and youth-targeted services and (3) a pharmacy-led fast-track ART refill program 
where stable ART patients can pick up medication without seeing a clinician. We 
explore attrition (defined as death or loss to follow-up at end of follow-up time) in 
these services using data from a large, established HIV cohort in Khayelitsha, a 
high HIV-prevalence, low-income area in South Africa.  
 
The first study examines whether males attending two male clinics (Male Clinic 1 
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and Male Clinic 2) show lower attrition compared to those attending general 
primary healthcare clinics. Using exposure propensity scores, we matched male 
clinic patients 1:1 to males at other clinics and used Cox proportional hazards 
regression to estimate the association between attrition and attending a male 
clinic. In the unmatched cohort, patients from male clinics (n=784) were younger 
than males from general clinics (n=2726), median age: 31.2 vs 35.5 years. Those 
initiating at male clinics had higher median CD4 counts at ART initiation (Male 
Clinic 1: 329 [210–431], Male Clinic 2: 364 [IQR: 260–536] vs. general clinics 258 
[IQR: 145–398] cells/mm3). The matched analysis included 1563 person-years 
among 1568 patients. Patients initiating ART at male clinics had lower attrition 
(HR: 0.83; 95% CI: 0.69–1.00). When matching and modelling was conducted for 
Male Clinic 1 and 2 separately, only the more established Male Clinic 1 showed a 
protective effect (HR 0.83; 95% CI: 0.65–1.07).  
 
The second study investigates whether attrition from care among youth (aged 
12–25) on ART is lower among youth attending two youth clinics (Youth Clinic A 
and Youth Clinic B) compared to those attending general primary healthcare 
clinics. We also conducted a sub-analysis of patients attending adherence clubs 
(a model of ART delivery led by a lay facilitator, including a peer support group).  
We hypothesized that the effect of peer support in adherence clubs might be 
enhanced by the age-specific clubs at the youth clinics. It may also be further 
enhanced by additional elements of the adherence club model offered only in 
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Youth Clinic A, including integration of family planning. Youth at the youth clinics 
were more likely than those at general clinics to have initiated ART before August 
2011, particularly those at Youth Clinic B (23% compared to 11% at general 
clinics). The distribution of age, sex, and CD4 count at ART initiation was similar 
across youth and general clinics. We observed a protective effect of youth clinics 
against attrition: HR 0.81 (95% CI: 0.70–0.93) for Youth Clinic A and 0.85 (0.74–
0.98) for Youth Clinic B, compared to youth at general clinics. Youth Clinic A club 
patients had lower attrition after joining an adherence club compared to general 
clinic patients in adherence clubs (crude HR: 0.56, 95% CI: 0.32–0.96; adjusted 
HR: 0.48, 95% CI: 0.28–0.85), while Youth Clinic B showed a smaller difference 
(crude HR: 0.83, 95% CI: 0.48–1.45; adjusted HR: 1.07, 95% CI: 0.60–1.90). 
 
The third study assesses attrition among patients in a pharmacy-led fast-track 
ART refill program compared to matched stable, otherwise healthy, patients who 
were eligible for the fast-track program at the same point in time and at the same 
facility but did not join. Matched pairs were followed from the date of the fast-
track patient’s first fast-track ART pick-up, and attrition was compared using Cox 
proportional hazards regression. Fast-track patients and matched controls had 
similar characteristics at ART initiation and at fast-track enrolment. Fast-track 
patients were less likely to have previously experienced tuberculosis (23% vs 
28%), diabetes (1% vs 7%) and hypertension (12% vs 27%), compared to those 
not in fast-track. Fast-track enrolment was highly protective against attrition (HR: 
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0.40; 95% CI: 0.31–0.51). We hypothesized that some of the association could 
be explained by confounding, arising from clinicians differentially referring 
patients to fast-track, possibly based on social, health, or mental health 
characteristics not reflected in the data. In a bias analysis using a plausible range 
of effects of such unmeasured confounding, the hazard ratio accounting for 
random and systematic error was 0.60 (95% interval: 0.42–0.89).  
 
All three studies show some protective effects of these differentiated models of 
service delivery against attrition. While stand-alone youth and male clinics are 
not feasible in all settings, and fast-track models may not be suited to all patients, 
these results suggest that multiple approaches tailored to specific populations’ 
needs can contribute to improving retention.   
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In South Africa 7.7 million people, or 13.2% of the population, are living with HIV 
[1]. This constitutes 20% of people living with HIV globally, and makes South 
Africa the country with the largest HIV-positive population [2]. In 2006, annual 
HIV deaths peaked at almost 300 000, and although prevalence has increased, 
annual deaths have steadily declined [1].  
 
The trend of declining mortality and improved health outcomes among people 
living with HIV has been observed in many contexts, and has been attributed to 
the development of more tolerable antiretroviral therapy (ART) regimens and the 
scale-up of ART programs [3–13]. Mathematical modelling of the South African 
epidemic has been used to estimate that the scale-up of ART prevented 1.72 
million deaths from 2000 to 2014 [1]. A review of data published between 2006 
and 2015 found that the life expectancy of HIV-positive people on ART ranged 
from 60% to 89% that of their HIV-negative counterparts of the same nationality, 
sex and age [8]. This review and a 2017 meta-analysis showed that, globally, life 
expectancies of people on ART have been increasing over time [8,14].  
 
In addition to improving and lengthening the lives of people living with HIV, ART 
also reduces HIV incidence by suppressing patients’ viral loads and reducing the 
probability of transmission [15–17]. If an HIV-positive person is on ART and has 
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an undetectable viral load, they are extremely unlikely to transmit the infection to 
their sexual partners. For example, in studies following couples where one 
partner was HIV-positive and on ART, no new transmissions were observed  
from a partner with an undetectable viral load in 1593 person-years of follow-up 
among men who have sex with men [18] and 10031 person-years among 
heterosexual couples [19]. In South Africa, modelling of the epidemic over the 
period 2015–2035 suggests  that a 10% increase in viral suppression would lead 
to a 14% reduction in incidence [20].  
 
Recognising these benefits, the South African public health system offers free 
ART to anyone testing positive for HIV, and the country has the largest ART 
program in the world. Despite the known benefits of ART, in South Africa in 2019 
34% of HIV-positive people were not on ART, HIV led to an estimated 69,162 
deaths, and there were over 180,000 new infections [1]. To improve patient 
outcomes, and reduce transmission, the health system needs to find ways of 
attracting and retaining more people in ART care.  
 
A key strategy in the scale-up of ART has been the introduction of ART 
distribution models where eligible patients require fewer individual clinician visits. 
Examples of such differentiated service delivery include (1) patient-led 
community adherence groups, where one patient collects and distributes 
medication to others in their community, and (2) pharmacy-led fast-track ART 
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refill programs, where stable patients can pick up their ART directly from the 
pharmacy without seeing a clinician. Other examples include community- and 
facility-based adherence clubs  which consist of groups of stable patients, and 
are led by a lay healthcare worker, who distributes medication and runs a support 
session [21]. These models benefit stable, otherwise healthy, patients through 
increased convenience and peer support, and have also helped to make the 
health system more efficient by freeing up clinicians’ time. There is a growing 
appreciation that focusing on improved efficiency in the management of stable 
patients is not sufficient to achieve complete ART coverage. To reach and retain 
patients, differentiated service delivery also needs to cater to specific contexts, 
clinical needs, and subpopulations [21,22]. Improved retention has been seen in 
models catering to specific and evolving needs of patients, including virally 
unsuppressed patients [23], youth [24–26], and postnatal mothers [27]. Within 
constraints, health systems should be flexible to the changing needs of patients 
over their lifetimes [28].  
 
Two populations that have been shown to have elevated attrition risk are males 
(compared to females) [29,30] and youth (compared to older adults) [31,32]. 
Given their increased risk, it is important to identify strategies to prevent attrition 
in these populations. The first two studies evaluate the effectiveness of clinics 
targeting males and youth in preventing attrition among these groups. The third 
study compares attrition from care between patients in pharmacy-led fast-track 
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ART refill program and matched patients in routine care.  
 
Setting 
All studies use routine clinical data from HIV patients on ART in Khayelitsha, a 
low-income area in Cape Town comprised of formal and informal housing with a 
population of approximately 500,000 people [33,34]. Compared with other areas 
in Cape Town, the Khayelitsha health sub-district has higher rates of HIV, 
maternal mortality, injury from violence, and non-communicable diseases [35]. In 
2006, 26% of life years lost in Khayelitsha were attributed to HIV/AIDS [35] and 
in 2017 one in three pregnant women in Khayelitsha was HIV-positive [36]. The 
Khayelitsha HIV treatment program began in 1999 and was the first in South 
Africa to provide HIV treatment in a primary care setting [37]. There are about 






Attrition from care among men initiating ART in male-only clinics compared 
with men in general primary healthcare clinics 
Introduction 
In most African settings, men are less likely to get tested for HIV, link to HIV care 
or initiate antiretroviral therapy (ART) than women [38–44]. Those who do are 
more likely to present to clinics later, with more advanced disease and have 
worse clinical outcomes [6,40,51–53,41,42,45–50]. A meta-analysis found that in 
low and middle-income countries, 20-year old males starting ART would on 
average live 22.9 more years (95% CI 18.4–27.5 years), compared to 33.0 years 
(95%CI 30.4–35.6 years) for females [14]. Multiple studies have shown men to 
have higher rates of attrition from HIV care programs than women 
[7,29,30,42,52,54–63]. In South Africa, ART coverage is substantially lower 
among adult males (58%) compared with adult females (64%) [1]. In 2017, 36% 
of the nearly 7 million HIV-positive adults living in South Africa were male, but 
males accounted for 52% of AIDS deaths [1]. Being on ART not only reduces 
mortality, but also decreases morbidity and transmission[17,64,65]. 
 
Explanations for men’s low attendance and poor outcomes include notions of 
masculinity that are at odds with both illness [66,67] and expected patient 
behavior [68], public health systems that are historically built around maternal 
and child health, and systematic under-funding of men’s services compared to 
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women’s [41,47,69,70]. Despite higher attrition among males on ART, few 
strategies have been developed to specifically address poor HIV outcomes for 
males in low and middle-income countries with generalized epidemics [46,47,69].  
 
In 2014, in response to low male engagement and retention in care, the City of 
Cape Town’s health department, supported by Médecins Sans Frontières started 
a male clinic, (“Male Clinic 1”)[37]. This service is staffed exclusively by males, is 
promoted as a males-only space, and offers HIV testing and counselling, ART 
initiation and dispensing, sexually transmitted infection (STI) diagnosis and 
treatment, and other primary healthcare services. In July 2016, another clinic 
following the same model (“Male Clinic 2”) began offering ART services at a 
small clinic above a transport hub. Both clinics are located in Khayelitsha, a high 
HIV prevalence, high-poverty peri-urban area in Cape Town. We evaluate this 
intervention by comparing attrition from care among men at these two male-only 
clinics to men attending six general primary healthcare clinics. 
 
Methods 
Study design  
We conducted a propensity score matched cohort study of adult males at primary 
care clinics that provide HIV care services to adult males in Khayelitsha, 
comparing attrition from ART care among men at two male-only clinics to men 
attending six general primary healthcare clinics.  
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Population and Setting 
The City of Cape Town’s Health department offers HIV care at 10 primary 
healthcare clinics in Khayelitsha, including two male-only clinics, six general 
primary healthcare clinics (with no particular male-targeted programs), and two 
youth-targeted clinics. Department of Health clinicians provide free services at all 
facilities, with support from non-governmental organizations who manage all lay 
adherence counselors at each facility. For the time period considered in this 
paper, Médecins Sans Frontières paid for and managed the counselor at Male 
Clinic 1, but not Male Clinic 2.  
 
The study population consisted of adult (18 years and older) males who first 
initiated ART between 1 January 2014 (the year that Male Clinic 1 opened) and 1 
April 2018 at the two male-only clinics or six general primary healthcare clinics. 
Youth-targeted clinics were excluded from the analysis as these clinics represent 
a separate novel model of targeted care, and do not provide care to men over the 
age of 25. Patients who had tuberculosis at ART initiation were excluded 
because these patients were often referred out of the male clinics for 
management at the general clinics. We excluded patients known to have initiated 
ART on a regimen not containing tenofovir (TDF) or efavirenz (EFV) as patients 
requiring non-tenofovir or non-efavirenz regimens at male clinics were generally 





All data for the first two studies came from routine patient data collected from 
patient folders at City of Cape Town clinics in Khayelitsha. Data capturers at 
each clinic capture data electronically from the patient folder after each patient 
ART visit. Data includes patient demographics, visits, regimens dispensed, 
laboratory results, and events such as deaths or transfers. I manually checked 
for missing CD4 count results on the National Health Laboratory System. 
 
Measures 
The exposure of interest was receiving HIV treatment at one of two male clinics 
compared with receiving care at a general clinic. Our primary outcome was 
attrition from HIV care, a measure including all patients who were lost to follow-
up or who died. Death was passively reported by families so it was assumed that, 
as reported in similar contexts, some patients who had died would have been 
misclassified as lost to follow-up in clinics [71–73]. Lost to follow-up was defined 
as being three months late for a scheduled visit with no subsequent visit. If a 
patient returns to care they are no longer considered lost to follow-up.  
 
The dataset was closed on 30 September 2018. Follow-up time for each person 
started on the date of ART initiation and ended on the last visit date before 1 
April 2018, regardless of their outcome. The six months between analysis closure 
and dataset closure allowed enough follow-up time to ascertain whether the 
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person returned to care or became lost to follow-up. Patients who transferred out 
were censored on their last visit date at their original clinic, even if the transfer 
was to another clinic represented in this dataset. If a patient’s last attended visit 
was the same as their ART initiation date, one day of follow-up was added to 
prevent them from being excluded from Kaplan-Meier and Cox proportional 
hazards analyses [74]. Baseline CD4 count was defined as the closest available 





Chained multiple imputation [75–77] was performed using the ice procedure in 
Stata [78,79] for missing values of baseline WHO disease stage and CD4 count. 
Missing data were assumed to be missing at random. We created 20 imputed 
datasets.  
Propensity score matching 
We used a matched exposure propensity score approach to control for 
confounding. Propensity scores were generated using logistic regression, with 
clinic type (male clinics vs general clinics) as the dependent variable. 
Independent variables were predefined potential confounders: baseline WHO 
stage, age, year and CD4 count, observed to be associated with both attrition 
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and male clinics. This process was repeated for each of the imputed datasets 
and an average propensity score for each observation was calculated across 
datasets [80]. The exposed were matched, in random order, 1:1 to the 
unexposed patient with the closest average propensity score (nearest neighbor 
matching), without replacement [81].  
Cox regression analysis  
We performed a Cox proportional hazards regression on the matched data to 
estimate the hazards ratio (HR) of attrition associated with attending male clinics 
compared to general clinics. The multiple imputed datasets were combined using 
Stata’s mi estimate feature, which uses Rubin’s methods [82] to adjust 
coefficients and standard errors for the variability between imputations. To adjust 
for any residual confounding after matching on propensity score, covariates were 
individually added to the model to observe their effect on the HR but none were 
retained as none met the threshold of changing the HR by more than 10%.  
 
Goodness of fit tests using Schoenfeld residuals suggested no evidence of 
violation of the proportional hazards assumption (p= 0.88). For the survival 
curves and model diagnostics, only the first  imputed dataset was used, because 
after propensity score generation and matching clinic type, outcome and 




We performed several sensitivity analyses. First, the full analysis was performed 
separately for each male clinic, to see if there was a difference in effect between 
the two clinics.  We did an additional analysis which excluded Male Clinic 1 
patients and follow-up time after the first two years of the clinic’s ART services, to 
see if any differences between the two male clinics could be explained by Male 
Clinic 1 being a more established clinic. Second, we used a prospective definition 
of our outcome in which a patient was considered lost to follow-up the first time 
there was a nine month gap in care, even if s/he later returned to care. The date 
of last visit before the gap in care was used as the outcome date.  Third, we 
considered the effects of ‘silent transfers’[83,84], where patients switched to 
another facility but were not captured as transfer-outs. We manually searched for 
results from patients who were lost to follow-up on the National Health 
Laboratory System, which contains laboratory results from all patients in the 
public sector, regardless of where they attend care. Patients were reclassified as 
transfers if they had a viral load (a routine HIV monitoring test) result within one 
year of their last known visit, at any primary healthcare facility. We excluded 
blood tests that were performed at tertiary care facilities as these were likely 
done because the patient presented with an illness, and did not necessarily 
indicate that the patient was in ART care. It is still possible that the reclassified 
patients were in fact lost to follow-up, and then returned to care nine months 
later, or presented sick at an ART clinic.  
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Quantitative bias analysis 
Unmeasured confounding could originate from residual confounding or from 
confounders that were not measured in the dataset and so cannot be controlled 
analytically. For example, males that choose to go to the male clinic may be 
more likely to be proactive in selecting a clinic of their choice, and therefore more 
engaged and more likely to stay in care. A hypothesized cluster of behavioural 
characteristics, including mental health and attitudes towards healthcare and 
female healthcare workers, may be associated with male clinic attendance and 
attrition. Considering this cluster of characteristics as a single confounder, we 
conducted a quantitative bias analysis.  
 
In order to quantify the effects of this unmeasured confounding, we hypothesized 
a plausible distribution of associations between the confounder and male clinic 
attendance, and between the confounder and attrition at any time. As we were 
concerned that protective effects may be explained by uncontrolled confounding, 
we considered only associations that, if properly adjusted for, would reduce any 
observed protective effect of male clinics against attrition. We quantify the effect 
of this range of associations on the observed effect of male clinics on attrition.  
 
We obtained a range of hypothesized associations between the confounder and 
attrition based on literature on risk factors for attrition, such as mental health, 
poverty, and substance use, which were not measured in our dataset. A meta-
13 
 
analysis of American studies found that patients with mental health diagnoses or 
symptoms had 6% lower retention (OR = 0.94; 95% CI = 0.90–0.99) [85]. A 
systematic review identified 52 studies of the association between ART 
adherence and depression globally, which found null effect sizes in 22 studies. 
Of the 18 studies that quantified the effects as risk ratios or odds ratios, 14 
showed a one- to two-fold increase in poor adherence in those with diagnosed 
depression [86]. Two studies found slightly larger associations: between 
depression and good adherence (OR=0.34, 95% CI: 0.18–0.64), and not being 
depressed and good adherence (OR=2.8, 95% CI: = 1.5–5.4). The remaining two 
studies focused on severe depression (OR=5.7, 95% CI: 1.7–18.6 and OR= 4.48, 
95% CI: 1.64–12.27). Another pooled meta-analysis of 11 studies conducted in 
sub-Saharan Africa found that good adherence (based on a mixture of self-report 
and pill count measures) was 55% lower among those with depression 
symptoms compared to those without (OR=0.45; 95% CI: 0.31–0.66). In the 
same review, a meta-analysis was not possible for five studies of the effects of 
alcohol use on adherence, which used heterogeneous alcohol use measures and 
showed effects  varying from harmful to positive[87]. It is unlikely that any cluster 
of confounding characteristics associated with male clinic attendance would have 
a greater effect on attrition than depression does on adherence. However, it is 
possible that the confounder has a larger effect on retention than that of mental 
health diagnoses or symptoms in American HIV cohorts (pooled OR = 0.94) [85]. 
We therefore hypothesized that confounding characteristics associated with male 
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clinic attendance and protective against attrition could lead to 0.5 to 0.9 times the 
risk of attrition, which we represent as a triangular distribution with a mode of 0.7.   
 
We represented uncertainty in the confounder exposure association by 
specifying the confounder prevalence as a triangular distribution with a mode of 
10% (range: 0–20%) in the general clinics. We assume a 1.5–2.5 times higher 
prevalence in the male clinics (triangular distribution, mode=2), resulting in a 
range of confounder prevalence of 0–50% in the male clinics.  It is unlikely that 
the confounder is more than 2.5 times more prevalence in the male clinics: this is 
a low-income area and we can assume that other non-confounding factors inform 
clinic choice such as convenience and transport costs.  
 
Using R [88], we ran a Monte Carlo simulation in which we sampled 100 000 
draws from each of these three distributions: (1) confounder-attrition relative risk, 
(2) confounder prevalence in general clinics, and (3) confounder-male clinic 
relative risk. For each simulation, the sampled values from the three distributions 
were used to calculate four values: the probabilities of confounder status for each 
outcome and exposure status. These probabilities were used to randomly impute 
confounder status for each record, based on their observed exposure and 
outcome status, using a Bernoulli trial. We calculated the HR for each simulation, 
adjusting for the simulated confounder. Random error was sampled from a 
normal distribution (mean=0, SD=standard error of the unadjusted HR) and 
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added to each adjusted HR. The resulting distribution of 100,000 HRs shows a 
range of results that incorporate (hypothesized) systematic and random error 
[89]. The median bias-adjusted HR is presented, along with a 95% interval (2.5–
97.5 percentile).  
 
We also explored a range of possible associations which would nullify any 
observed exposure-outcome association and reported the e-value[90] for the 
observed HR using Stata 14 [91].  
 
Results 
We had data for 31,578 patients ever on ART in male-targeted or general 
primary healthcare clinics run by City Health in Khayelitsha. After exclusions, the 
analytic dataset included 3510 observations: 462 observations from Male Clinic 
1, 322 from Male Clinic 2, and 2726 eligible matched comparisons from other 




Figure 1 Flow chart for inclusion in analysis   
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Patients at Male Clinic 2 were most likely to have initiated ART recently, with 
89% of patients initiating after ART eligibility criteria were removed in 2016, 
compared to 39% in the general clinics. Men initiating ART at male clinics were 
younger than those in the general clinics (31.2 (IQR: 26.9–36) compared to 35.5 
(IQR : 30.3–42.2) years old). General clinics had a higher proportion of patients 
initiating ART at WHO disease stages 2–4 (31%) compared to Male Clinic 1 (7%) 
and Male Clinic 2 (2%). Men initiating treatment in the male clinics had a higher 
median CD4 count than general clinics (Male Clinic 1: 329 (210–431), Male Clinic 
2: 364 (IQR: 260–536) vs. general clinics 258 (IQR: 145–398) cells/mm3). 
General clinics had a higher proportion of missing data on disease stage at ART 
initiation and CD4 count (Table 1).  




Table 1 Distribution of covariates by clinic group, before and after imputation and propensity score matching 
 Before multiple imputation and propensity score 
matching 
After multiple imputation and 
propensity score matching  
Male Clinic 1 Male Clinic 2 General clinics Male clinics General clinics 
N 462 322 2726 784 784 
Year of ART initiation 
 
    
2014 9% 0% 19% 5% 6% 
2015 27% 0% 25% 16% 14% 
2016 29% 25% 26% 27% 27% 
2017 27% 58% 25% 40% 41% 
2018 8% 17% 6% 11% 11% 
After 1 Sept 2016† 44% 89% 39% 63% 60% 
Age      
18–24 15% 15% 7% 15% 14% 
25–34  55% 59% 41% 57% 57% 
35+  30% 26% 52% 28% 29% 
Median age (years) (IQR) 31.6 (27.4–36.9) 30.7 (26.6–35.3) 35.5 (30.3–42.2) 31.2 (26.9–36) 31.3 (27.1–36.2) 
Baseline WHO stage  
 
    
Stage 1 89% 93% 59% 95% 91% 
Stage 2 4% 2% 16% 3% 6% 
Stage 3 3% 0% 12% 2% 3% 
Stage 4 1% 0% 3% 1% 0% 
Stage 2–4 7% 2% 31% 5% 9% 
Missing 3% 4% 10% - - 
Baseline CD4 Count (cells/mm3)      
<200 22% 11% 34% 19% 26% 
200–349 32% 32% 28% 33% 26% 
350–500 32% 25% 19% 30% 26% 
>500 13% 26% 11% 19% 22% 
Missing 1% 5% 8% - - 
Median CD4 count (IQR) 329 (210–431) 364 (260–536) 258 (145–398) 343 (233–455) 335 (193–484) 
† On 1 September 2016 CD4 thresholds were removed as eligibility requirements for ART initiation, allowing anyone that 
tested positive to initiate ART immediately 
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Before imputation or propensity score matching, Male Clinic 2 had a higher risk 
of 12-month attrition (32%) compared to Male Clinic 1 (23%) or general clinics 
(24%) (Table 2). Risk of attrition by six and 12 months was associated with more 
recent ART initiation and younger age. Baseline WHO stage was not associated 
with attrition, but missing information was associated with higher attrition and 
those healthier at baseline were at a slightly higher risk of attrition. We observed 
24% attrition at 12 months for those with a CD4 count below 200 cells/mm3, 
compared to 28% for those with a CD4 count above 500 cells/mm3.  
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Table 2 Attrition from Care at 6 and 12 months by covariates (without imputation 
or propensity score matching) 
 
Attrition by 





Total 19% 24% 
Clinic   
 General Clinics 18% 24% 
 Male Clinic 1 18% 23% 
 Male Clinic 2 26% 32% 
Initiating in year:   
 2014 15% 21% 
 2015 14% 19% 
 2016 18% 26% 
 2017 25% 33% 
 Guidelines CD4<350 (before 2015) 15% 21% 
 Guidelines CD4<500 (1 Jan 2015– 31 Aug 2016) 15% 22% 
 After Universal Test and Treat (1 Sept 2016) 24% 31% 
Age   
 18–25 years 22% 28% 
 25–35 years 20% 26% 
 35+ years 16% 22% 
WHO stage at initiation   
 Stage 1 19% 25% 
 Stage 2 17% 21% 
 Stage 3 18% 24% 
 Stage 4 13% 18% 
 Stage 2–4 17% 22% 
 Stage missing 21% 29% 
Baseline CD4 Count (cells/mm3)   
 <200 18% 24% 
 200–350  18% 24% 
 350–500 19% 23% 
 >500 21% 28% 
 CD4 count missing 21% 25% 
† 6-month retention is only presented for those who initiate ART more than nine 
months before dataset closure 
‡12-month retention is only presented for those who initiate ART more than 15 
months before dataset closure. 
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Propensity score estimation and matching 
For male clinic patients, the median propensity score predicting the probability of 
attending a male clinic was 0.35 (IQR: 0.23–0.46), compared to 0.16 (IQR: 0.06–
0.28) among general patients (Appendix 1, Figure 9). After matching, the median 
propensity score was 0.35 for both male clinics (IQR: 0.23–0.46) and general 
clinics (IQR: 0.23–0.43).  
 
Propensity score matching reduced the association between exposure and 
covariates, but there were still small differences in terms of ART start date, age, 
disease stage and CD4 count at initiation (Table 1 and Appendix 1, Figure 10).  
 
Twelve-month attrition in the matched general clinic patients is 29%, compared to 
24% overall among eligible total general clinic males. Compared to males that 
were not matched to a male clinic patient, matched general clinic patients 
initiated ART at later dates, younger age, higher CD4 counts and less advanced 
disease stage (see also Figure 10 in Appendix 1).   
Analysis of matched cohort 
The matched cohort (N=1568) represented a total of 1568.9 person-years, 807.6 
of which were in the general clinics and 761.3 of which were in the male clinics.  
Kaplan-Meier curves for the matched cohort show greater attrition (loss to follow-
up or death) among men at general clinics, compared to male clinics (Figure 2).  
   




Figure 2 Kaplan-Meier survival estimates for matched cohort, by clinic type 
 
There was a small association between type of clinic and attrition (HR 0.83 (95% 
CI: 0.69–1.00) for male clinic patients compared to matched patients at general 
clinics) (Table 3).  
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Table 3 Results from Cox Regression Models showing effect of male clinics (vs. 
general clinics) on attrition 







Primary analysis using propensity-
score matched cohort, no covariates 
included 
0.83 
(0.69–1.00) 1563 448 
1 Male Clinic 1 and matched controls† 0.83 (0.65–1.07) 1178 250 
2 Male Clinic 2 and matched controls† 1.01 (0.75–1.36) 415 180 
3 
Include only Male Clinic 1 and 
respective matched controls from 
first two years of clinic operating‡ 
0.75 
(0.47–1.17) 474 92 
4 Prospective definition of outcome§  0.71 (0.60–0.85) 1447 506 
5 Not considered lost to follow-up if patient had viral load within 1 year 
0.82 
(0.68–0.99) 1563 431 
Quantitative bias analysis of main model results (95% interval)   
 HR adjusted for systematic error 0.86 (0.83–0.92) 1563 448 
 HR adjusted for systematic and random error 
0.86 
(0.71–1.04) 1563 448 
†not necessarily the same general clinic comparison group as in the main model, as 
propensity scores were generated again using only the included male clinic.  
‡i.e. excluding all male clinic patients initiating ART after 1 June 2016 and their 
respective controls, and ending follow-up time for male clinic patients on 1 June 2016 
§the first time there is a nine-month gap in care patients are considered lost to follow-up 




In separate analyses of each male clinic cohort compared to newly matched 
cohorts of general clinic patients, Male Clinic 1 patients had lower attrition (HR 
0.83; 95% CI: 0.65–1.07), but Male Clinic 2 patients did not (HR: 1.01; 95% CI: 
0.75–1.36) (Table 3). In the full matched cohort (both male clinics), a stronger 
protective effect was observed when changing the definition of the outcome to 
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include a gap of nine months or more, regardless of whether a patient returned to 
care (HR: 0.71; 95% CI: 0.60–0.85). Similar results were found reclassifying 
failures who had a viral load result within one year of their last visit (HR: 0.82; 
95% CI: 0.68–0.99).  
Quantitative Bias Analysis 
Incorporating total error, the median adjusted HR is 0.86 (95% interval: 0.71–
1.04) (Table 3). Adjusting for the hypothesized distributions of confounder 
prevalence in general clinics, confounder-male clinic associations, and 
confounder-attrition associations, there is still a small protective effect of male 
clinics on attrition (Appendix 1, Figure 8).   
 
The e-value was 0.66, meaning that the true effect of male clinics on attrition 
would be null if there were an unmeasured confounder associated with both 
attrition and clinic type with a risk ratio of 0.66 (Appendix 1, Table 9).  
Discussion 
This study compared attrition from care in two male-targeted clinics and six 
general primary healthcare clinics in a low-resource, high HIV prevalence area. 
Males at the male-targeted clinics had a somewhat lower risk (HR 0.83; 95% CI: 
0.69–1.00) of attrition than those in general clinics, adjusting for baseline clinical 
and demographic characteristics using a matched propensity score approach. 
Separate analyses of the two male clinics showed a protective effect only for 
Male Clinic 1 when compared to general clinics.  
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 Men initiating ART at the male clinics were younger and healthier than those 
initiating in the general primary healthcare clinics. This may be partly because, 
while not quantified in this paper, a large proportion of male clinic ART patients 
initially presented with STIs [92], which men may not be willing to reveal to 
female healthcare providers [93]. STI treatment is an important opportunity for 
HIV diagnosis and treatment initiation for males, who otherwise have fewer 
opportunities to interact with the healthcare system than women [94,95]. Male 
clinics might also be more successful at linking newly diagnosed patients to ART 
care earlier in HIV disease progression. Earlier ART initiation also reduces the 
risk of transmission [17]. 
 
Despite being younger and healthier at ART initiation, male clinic patients 
(particularly those at Male Clinic 2) had a higher risk of six- and twelve-month 
attrition than general clinic patients in a crude analysis (Table 2). This is 
consistent with other literature showing that being younger and having fewer 
comorbidities makes patients more likely to drop out of care, possibly because 
they do not see an immediate benefit of ART [96,97]. This is an important 
consideration when evaluating programs that improve uptake of testing or earlier 
ART initiation: attrition may appear to worsen because of changing baseline 
characteristics.   
 
Through propensity score matching, we created a general clinic cohort that was 
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more comparable to the male clinic group in terms of baseline health and 
demographic characteristics. In this analysis, we found a somewhat lower 
attrition from male clinics than from general clinics. When defining attrition as the 
first nine-month gap in care, regardless of whether men returned to the clinic, the 
observed effect was more protective. This suggests that male clinics may be 
particularly protective against shorter disengagements from care, which is a 
growing concern with increasing ART duration [28,98,99]. It is possible that 
creating a male-only environment can make clinics more acceptable to men, 
possibly through helping them to overcome social and cultural barriers to care 
[66–68], including complicated gender dynamics with female healthcare 
providers [100], and leading to improved retention in care. Research has also 
suggested that men’s healthcare experiences are influenced by peers and social 
networks[101], so it is possible that the benefits of the service are enhanced 
through these relationships.  
 
In an analysis of Male Clinic 2 compared to general clinics, no protective effect 
was observed. Although Male Clinic 2 only began ART services in mid-2016, 
Male Clinic 1’s lower attrition cannot be explained by the fact that the older clinic 
has had longer to establish itself, as protective effects were also observed in the 
first two years of Male Clinic 1’s ART services. It is possible that Male Clinic 2 
attracted a more transient population as it is located at a transport hub, where 
men may have attended when convenient, as opposed to selecting a clinic near 
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their homes. Most attrition happened soon after ART initiation. In a context where 
people have precarious livelihoods, with 38% unemployment in Khayelitsha, time 
and transport costs may present early barriers to continuing ART care [33,102]. It 
is also possible that support from Médecins Sans Frontières via the lay 
adherence counselor provided at Male Clinic 1 differed from the standard of care 
at Male Clinic 2 and other clinics, where counselors were provided by another 
organisation and paid less than the Male Clinic 1 counselor. Nonetheless, Male 
Clinic 2 was successful in initiating younger, healthier men, with comparable 
retention to general clinics, when controlling for these factors.  Despite favorable 
results compared to general clinics, there was 23% attrition by 12 months at Male 
Clinic 1. This likely reflects the myriad documented challenges to continued 
engagement in ART care including competing responsibilities, social stigma, 
mental health issues, migration and substance abuse [103–109]. 
 
Data for this analysis was limited to laboratory records and clinical data from 
selected clinics, and may have underestimated true mortality. In addition, data 
quality may differ between clinics, leading to differential misclassification of loss 
to follow-up. However, the sensitivity analysis incorporating laboratory data to 
approximate “silent transfers” did not substantially change our results. A second 
limitation is the potential for unmeasured confounding, stemming from self-
selection of males into the male clinics. Our quantitative bias analysis showed 
that even if there were reasonably strong confounder-exposure and confounder-
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attrition associations, there would still be a protective effect of male clinics on 
attrition. The hypothesized confounding characteristics in the male clinic patients 
may also increase the risk of attrition. For example, characteristics that are 
associated with a strong aversion to female healthcare workers may also be 
associated with other health behaviors such as avoidance of clinics in general, 
and non-disclosure of their HIV status, which is associated with poorer 
retention[110,111]. If this is the case, then the observed effect sizes are 
underestimates and the true effect of male clinics may be more protective.   
 
In conclusion, in an environment where engaging health services may be 
perceived as a sign of vulnerability [112], contrary to hegemonic masculine ideals 
[113], these clinics aim to create explicitly male spaces to make men feel more 
comfortable attending the clinic and reduce attrition from care. Our results 
suggest this has been successful at Male Clinic 1, and less so at Male Clinic 2, 
possibly because of less counsellor support, or a more transient population. Both 
clinics successfully attracted younger, healthier males than the general clinics, 
reaching men sooner after HIV infection. Stand-alone male-only clinics may not 
always be feasible, particularly in lower-resource, or lower population density 
settings. However these findings support smaller-scale interventions such as 
increasing the proportion of male nurses and lay counselors in public clinics, or 
strengthening male-targeted STI treatment as an entry-point for males. Further 
research could explore other ways of designating male services such as 
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separate spaces, rooms, programs, queues, entrances, or operating hours for 
men, which may also help to improve confidentiality and counter the perception 
of healthcare facilities as female spaces.   




Attrition from care among youth initiating ART in youth-only clinics 
compared with general primary healthcare clinics 
Introduction 
Background and Rationale 
As of 2017, HIV prevalence among South African youth aged 15–25 was 7.1% 
[1], with 88000 new infections occurring in this age group annually, translating to 
an annual incidence of 1% [114]. Among HIV-positive youth aged 15–24, just 
40% were on antiretroviral therapy (ART) in 2017, compared to 63% of HIV 
positive adults aged 25–49 [115]. A review of adolescent HIV care in South Africa 
identified six studies measuring retention in care, all of which showed poorer 
retention of youth compared to adults (ORs 1.55–2.25) [116]. Poorer youth 
retention has been observed throughout the region: a large cohort analysis of 
ART patients in sub-Saharan Africa found youth (15–25) to have a higher risk of 
attrition (adjusted hazard ratio: 1.59, 95% CI:  1.52–1.67) than adults over 25 
years old [31]. Retaining people living with HIV in ART care benefits individual 
patients, public health systems, and society by improving patient outcomes and 
reducing transmission [17,19,65,117]. As youth on ART are a growing population 
[118], facing many years on ART, it is important to identify effective strategies to 
address youth-specific needs and prevent youth attrition from HIV care.  
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Strategies to make ART services more ‘youth-friendly’ and facilitate the transition 
from child to adult care have included various combinations of counselling and 
support services, peer support, dedicated youth times, and staff sensitization 
[119–122]. Evaluations of such interventions have yielded mixed results. A 2019 
review identified two interventions associated with reduced youth attrition [122]. A 
dedicated adolescent clinic (n=88) showed improved retention in care compared 
to standard clinic care in a South African setting [123]. In a Malawian hospital, 
attending a teen club provided adolescents (10–19 years old) with dedicated 
clinic time, services and peer support, and was associated with a large decrease 
in attrition (OR: 0.27; 95% CI: 0.16–0.45) [124]. A recent study in Zimbabwe 
randomized an intensive treatment support program, including an individually 
assigned community  adolescent  treatment  supporter, monthly  support  groups, 
text  messages, calls, home  visits,  and  clinic-based  counselling. Adolescents 
in intervention clinics had improved virological outcomes (prevalence ratio: 0.58; 
95% CI: 0.36–0.94) and attendance (prevalence ratio: 0.80; 95% CI: 0.32–2.02), 
suggesting that peer support and enhanced counseling play an important role in 
youth retention and ART adherence [125].  
      
Two youth HIV clinics (referred to here as Youth Clinic A and Youth Clinic B) in 
Khayelitsha, South Africa, specifically aim to attract and retain youth in care. Both 
facilities offer services, including HIV testing and ART initiation and management, 
exclusively to youth between 12 and 25 years of age. While Youth Clinic A has 
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received more support in developing a tailored youth model [126], both clinics 
aim to foster a youth-friendly environment by creating an exclusive space for 
youth.  
 
HIV-positive youth (aged 12–25) are a growing population who will potentially be 
on ART for many years. Reducing the high rates of attrition in this group is 
important to reduce mortality, transmission and drug resistance. Through slightly 
different models, both Khayelitsha youth clinics attempt to address some of the 
psycho-social and provider-related causes of youth attrition. To date no 
evaluation of overall retention in care compared with other facilities has been 
done for either youth clinic.  
Methods 
Study design  
We conducted a cohort study of individuals aged 12–25 years at primary care 
clinics that provide HIV care services to youth in Khayelitsha, matched on 
propensity score, to compare attrition between those attending youth clinics and 
those attending general primary healthcare clinics.  
Population and Setting 
The City of Cape Town’s Health department offers HIV care at 10 primary 
healthcare clinics in Khayelitsha. The clinics include two youth-only clinics, six 
general primary healthcare clinics (serving all age groups), and two male-
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targeted clinics.  
 
The study population consists of HIV-positive youth aged 12–25 years who first 
initiated ART between 1 January 2008 (the year that Youth Clinic A started 
offering ART) and 1 April 2018 at one of the two youth-only clinics or at one of six 
general primary healthcare clinics. The male-only clinics were excluded from the 
analysis as they represent a separate novel model of targeted care, and do not 
provide care to females. Patients who had tuberculosis at ART initiation were 
excluded because these patients were often referred out of the youth clinics for 
management at the general clinics.  
Youth Clinics 
Both youth clinics provide primary health care services, including contraception, 
HIV testing, STI screening and basic curative services, exclusively to youth 
between 12 and 25 years of age. Since 2008, both youth clinics have offered 
ART to eligible HIV-positive youth, initially supported by Médecins Sans 
Frontières. In 2010, the City of Cape Town’s health department fully took over 
the ART services at both clinics, although Médecins Sans Frontières continued to 
give support to Youth Clinic A, primarily through lay adherence counselors. Lay 
adherence counselors are a key cadre supporting the retention of ART patients 
[127–129]. They are managed by non-profit organizations at all clinics in 
Khayelitsha, including the youth clinics. From 2011, lay counsellors at Youth 
Clinic A were managed by Médecins Sans Frontières, who trained younger 
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counsellors to be sensitive to the needs of youth [130].  
 
In Khayelitsha, many stable ART patients receive their medication in adherence 
clubs, patient groups that meet every 2–4 months in a community or facility 
venue where they are counselled as a group by a lay facilitator on ART 
adherence and other HIV-related issues. At one annual club visit, patients see a 
nurse or doctor for a clinical visit, where their viral load blood results are also 
reviewed. To be eligible to join and remain in an adherence club, patients are 
required to be stable on ART and have a suppressed HIV viral load [131,132]. 
This model has proven to be acceptable, scalable, and effective, while also 
providing peer support [133–141]. In general clinics, youth are typically in clubs 
with people of all ages. In youth clinics, peer support from other youth might 
enhance the benefit of clubs.  
 
Youth Clinic A further divides clubs by age, differentiating between youth of 
school-going age and those over the age of 18. Youth of different ages have 
different challenges, but social support has been identified as an important 
facilitator to engaging in care. Youth clubs provide this support in an age-
appropriate way. When appropriate, youth transition from younger to older youth 
clubs, reducing the difficulty of transitioning to adult care [119–121]. In addition, 
at Youth Clinic A, adherence clubs include family planning services. Integration 
of other services and social support have been identified as potential ways of 
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addressing youth-specific HIV care needs [142,143]. Youth Clinic A is also 
unique in that adherence clubs can be joined immediately after ART initiation, 
unlike typical adherence clubs which may only begin 6–12 months after initiation. 
Youth stable on ART receive medication refills in the group while newly initiated 
youth are given refills by the club nurse during a clinical consultation taking place 
immediately after the group [24,130]. 
 
Measures 
We investigated the effect of receiving HIV treatment from one of two youth 
clinics compared with receiving care at a general clinic on attrition. Attrition was 
defined as loss to follow-up or death. Deaths were not actively ascertained if they 
took place away from the clinic, so it was assumed, as reported in other contexts 
[71–73], that deaths were likely misclassified as loss to follow-up in clinic data. 
Loss to follow-up was defined as being three months late for a scheduled visit 
with no subsequent visit.  
 
The dataset was closed on 30 September 2018. For time-to-event analyses, 
follow-up time for each person started at date of ART initiation and ended on the 
last visit date before 1 April 2018. The six months between analysis closure and 
dataset closure allows enough follow-up time to ascertain whether they returned 
to care or became lost to follow-up. Patients who transferred out were censored 
on their last visit date at their original clinic, even if the transfer was to another 
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clinic represented in this dataset. Patients in care were censored on their 26th 
birthday, as this is when they would have been required to transfer out of the 
youth clinic. If a patient’s last attended visit was the same as their ART initiation 
date, one day of follow-up was added to allow for inclusion in time-to-event 
analyses [74]. Baseline CD4 count was defined as the closest available result to 
the date of ART initiation, between 180 days before and 30 days after initiation.  
Analysis 
Multiple imputation  
Missing values of baseline WHO disease stage, CD4 count and regimen were 
assumed to be missing at random and imputed. Chained multiple imputation [75–
77] was used to create 20 imputed datasets using the ice procedure in Stata 
[78,79]. 
Propensity score matched analysis  
Propensity score matching was used to create a group of general clinic patients 
comparable with youth clinic patients [144,145]. Separate analyses were 
conducted for each youth clinic: Youth Clinic B was excluded from the Youth 
Clinic A analysis, and vice versa. For each analysis, propensity scores were 
generated using logistic regression, with clinic type (youth vs general clinic) as 
the dependent variable. Independent variables were ART initiation date and 
WHO disease stage, as these were associated with the exposure (clinic type) 
and the outcome (attrition). This process was repeated for each of the imputed 
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datasets and an average propensity score for each observation was calculated 
across datasets [80]. Each youth clinic patient was matched 1:1 to a general 
clinic patient based on their average propensity score (averaged across the 20 
imputed datasets), using nearest neighbor matching without replacement.   
 
We performed a Cox proportional hazards regression on both matched datasets 
to estimate the hazard ratio (HR) of attrition associated with attending the 
respective youth clinic compared to general clinics. The multiple imputed 
datasets were combined using Stata’s mi estimate feature, which uses Rubin’s 
methods[82] to adjust coefficients and standard errors for the variability between 
imputations. To adjust for any residual confounding after matching on propensity 
score, covariates were individually added to the model to observe their effect on 
the HR, but none changed the HR by more than 10%.  
 
Proportional hazards assumption was assessed with chi-squared goodness of fit 
tests and graphically using Kaplan-Meier and log-log plots (Appendix 2). For 
model diagnostics, only the first imputed dataset was used, because after 
propensity score generation and matching clinic type, outcome and outcome date 
were identical across datasets.  
Adherence club analysis 
As described above, adherence clubs differed between Youth Clinic A, Youth 
Clinic B, and general clinics. We conducted a sub-analysis, including only 
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patients who attended an adherence club before the age of 26. We compared 
overall attrition from the time of first adherence club visit in a Cox proportional 
hazards model, by clinic type (Youth Clinic A and B, compared to reference 
category of general clinics). 
Sensitivity analyses 
We performed several sensitivity analyses to determine whether propensity score 
matching methods and the definition of the outcome affected the results. First, 
ART guideline era, as a categorical variable, was included in the propensity 
score models as an alternative to ART initiation date. Three changes in eligibility 
guidelines occurred during the follow-up period, and the initiation of healthier 
patients, as well as health system impacts of expanding programs, might have 
affected patient outcomes. These gradual shifts, as well as other secular trends, 
are adjusted for in the main analysis by including ART initiation date in the 
propensity score model, but it is possible that the guideline era of ART initiation is 
a better measure of this confounder. Second, we used the full unmatched 
dataset to estimate the effect of clinic type, defined as a multi-level exposure 
(Youth Clinic A and B, compared to reference category of general clinics). We 
estimated the crude HRs, HRs adjusted for ART start date, and HRs adjusted for 
ART start date and WHO stage. Finally, a prospective outcome definition was 
used where a patient was considered lost to follow-up the first time there was a 
nine month gap in care, even if they return to care at a later date. The date of last 
visit before the gap in care was used as the outcome date. The HRs described 
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above were all estimated for this definition of the outcome.   
Quantitative bias analysis 
Unmeasured confounding may arise from self-selection into youth clinics. The e-
value is a measure that quantifies a confounder-attrition and confounder-youth 
clinic association needed to explain away any observed association between 
clinic type and attrition [90]. E-values were calculated for HRs associating Youth 




Of 34245 ART patients from youth and general clinics run by City Health in 
Khayelitsha, 5738 (17%) were included in this analysis: 1383 observations from 
Youth Clinic A, 1299 observations from Youth Clinic B, and 3056 eligible 
comparisons from other clinics (Figure 3).  




Figure 3 Flow chart for inclusion in analysis  
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Patients at the youth clinics were more likely than those at general clinics to have 
initiated ART before August 2011, particularly those at Youth Clinic B (23% 
compared to 11% at general clinics). The median age of ART initiation was 
similar across Youth Clinic A (median 22.2; IQR: 20.4–23.5), Youth Clinic B 
(median 21.8; IQR: 20–23.3), and general clinics (median 22.4; IQR: 20.4–23.8), 
as was the proportion of males. General clinics had a slightly higher proportion of 
patients initiating ART at WHO disease stages 2–4 (29% compared to 20% at 
Youth Clinic A and 25% at Youth Clinic B). CD4 count at ART initiation was 
similar across the clinics (Table 4). 




Table 4 Distribution of covariates by clinic group, after imputation (before and after propensity score matching) 
 
General clinics 
(before matching) Youth Clinic A 
Matched 
controls Youth Clinic B 
Matched 
controls 
N 3056 1383 1383 1299 1299 
Era of ART initiation by CD4 count eligibility cut-off 
  CD4<200 (before Aug 2011) 11% 16% 14% 23% 18% 
  CD4<350 (Aug 2011–31 Dec 2014) 31% 31% 33% 31% 37% 
  CD4 <500 (1 Jan 2015–31 Aug 2016) 29% 25% 24% 24% 24% 
 All eligible (after 1 Sept 2016) 28% 28% 28% 22% 22% 
Age at ART initiation    
  12–17 years 9% 8% 9% 9% 9% 
  18–25 years 91% 92% 91% 91% 91% 










(20.4–23.8) Sex      
  Male 11% 11% 11% 9% 11% 
Baseline WHO stage    
  Stage 1 71% 80% 82% 75% 77% 
  Stage 2 16% 14% 11% 11% 11% 
  Stage 3 10% 5% 5% 11% 10% 
  Stage 4 3% 1% 1% 3% 2% 
  Stage 2–4 29% 20% 18% 25% 23% 
Baseline CD4 Count (cells/mm3)    
 <100 9% 6% 8% 9% 10% 
 100–199 15% 16% 16% 15% 16% 
 200–349  33% 40% 34% 36% 36% 
 350–500 24% 21% 23% 23% 21% 
  >500 19% 17% 20% 17% 17% 
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ART regimen at initiation     
  EFV-free regimens 6% 9% 8% 11% 9% 
  TDF-free regimens 9% 10% 10% 11% 12% 
Adherence clubs      
  Ever in club at clinic (before age 26) 19% 20% 19% 13% 18% 














% six-month attrition 21% 15% 20% 17% 20% 
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Before propensity score matching, overall 12-month attrition was 25%, and 
general clinics had somewhat higher attrition (27%) compared to Youth Clinic A 
(22%) and Youth Clinic B (24%) (Table 5). Those initiating ART after CD4 
eligibility criteria were removed (1 September 2016) had a 35% chance of 12-
month attrition, compared to 18% in those initiating ART before August 2011. 
This difference was reflected in all clinics, and greatest for general clinics (38% 
after September 2016, compared to 28% at Youth Clinic A). Initiating treatment 
before the age of 18 was associated with slightly lower 12-month attrition (22% 
vs 26%) than initiating ART at older ages. Attrition at 12 months was lower 
among those initiating at WHO disease stage 1 (26%) compared to stages 2–4 
(19%); and also lower for those with CD4 counts of 100–200 cells/mm3 (19%) 
compared to higher CD4 counts and those <100 cells/mm3 (26%). Higher 12-
month attrition was observed in those initiating on TDF-EFV regimens compared 
to those on both non-TDF regimens and non-EFV regimens (Table 5 see 
Appendix 2, Table 12 for breakdown by clinic type). 
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Table 5 Attrition from Care at 6 and 12 months by covariates (without imputation 
or propensity score matching) 
 
Attrition by 6 
months 
Attrition by 12 
months 
 N=5157†  N=4540‡ 
Total 19% 25% 
Exposure group  
  General clinics 21% 27% 
  Youth Clinic A 15% 22% 
  Youth Clinic B 17% 24% 
Sex   
  Male 18% 24% 
  Female 19% 25% 
Era of ART initiation (by CD4 count eligibility criteria)  
  <200 (before August 2011) 11% 18% 
  <350 (Aug 2011–31 Dec 2014) 16% 22% 
  <500 (1 Jan 2015 – 31 Aug 2016) 19% 27% 
  All eligible (After 1 Sept 2016) 28% 35% 
Age   
  12–17 years 16% 22% 
  18–25 years 19% 26% 
WHO stage at initiation 
  Stage 1 19% 26% 
  Stage 2 14% 18% 
  Stage 3 14% 19% 
  Stage 4 23% 28% 
  Stage 2–4 15% 19% 
Stage missing 29% 36% 
Baseline CD4 Count (cells/mm3)  
 <100 17% 26% 
 100–199 15% 19% 
 200–349  17% 23% 
 350–500 21% 29% 
 >500 23% 30% 
 CD4 count missing 19% 28% 
ART Regimen at initiation 
 EFV-free regimens 11% 15% 
 TDF-free regimens 12% 17% 
 TDF-EFV regimens 19% 26% 
 missing regimen information 29% 38% 
Ever in adherence club at clinic 0% 2% 
Never in adherence club at clinic 23% 31% 
† 6-month retention is only presented for those who initiate ART more than nine months 
before dataset closure 
‡12-month retention is only presented for those who initiate ART more than 15 months 
before dataset closure. 
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Propensity score matched cohorts 
After matching, the general clinic median propensity scores were identical to the 
youth clinics’ in both analyses. In both matched cohorts, propensity score 
matching reduced the association between clinic type and ART initiation era, and 
clinic type and WHO stage (Table 4). In the matched cohorts, six-month attrition 
was substantively higher among general clinic patients compared to youth clinic 
patients (Table 5).  
Matched and unmatched cohorts  
The matched propensity score cohort for Youth Clinic A included 833 events and 
4367 person years (2269 in general clinics and 2098 in Youth Clinic A). The 
Youth Clinic B analysis included 804 events and 4341 person years (2276 in 
general clinics and 2065 in Youth Clinic B). Kaplan-Meier curves for the matched 
cohorts are presented in Figure 4 showing lower risk of attrition for both youth 
clinics compared to general clinics.  
  




Figure 4 Kaplan-Meier survival estimates for matched cohorts, by clinic type 
Table 6 (row 1) shows HRs from matched propensity score models, where ART 
start date and WHO disease stage are included in the propensity score model. 
Compared to propensity score matched general clinic patients, there is a 
protective effect of youth clinics against attrition: HR 0.81 (95% CI: 0.70–0.93) for 
Youth Clinic A and 0.85 (0.74–0.98) for Youth Clinic B.      
Sensitivity analyses 
Results were similar when start date and guideline era were included in the 
propensity score model (along with WHO disease stage). Results in the crude 
Cox model (no propensity score matching) were similar to the matched 
propensity score analysis, and adjustment for covariates resulted in little or no 
change to the crude HR. Changing the definition of the outcome to include a gap 
of nine months or more, regardless of whether a patient returned to care, 
strengthened the protective effect of youth clinics against attrition, compared to 
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general clinic patients, for all models. In the primary propensity score matched 
model the prospective definition strengthened the effect size. The HR was 
reduced from 0.81 to 0.68 (95% CI: 0.60–0.76) for Youth Clinic A and 0.85 to 
0.72 (0.64–0.81) for Youth Clinic B (Table 6). 
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Table 6 Cox Regression Models of attrition risk of youth clinic compared to general clinic patients 
Method Variables adjusted for/included in propensity score model 
HR of risk of attrition in youth clinic 
vs. general clinics (95% CI) 
Youth Clinic A Youth Clinic B 
Full cohort Analyses 
Matched propensity 
score approach† 
start date and WHO disease stage  0.81 (0.70–0.93) 0.85 (0.74–0.98) 
guideline era and WHO disease stage  0.74 (0.65–0.85) 0.90 (0.78–1.03) 
No matching, combined 
Cox model including 
Youth Clinic A & B‡ 
crude 0.78 (0.69–0.88) 0.80 (0.71–0.90) 
adjusting for start date 0.80 (0.71–0.91) 0.86 (0.76–0.97) 
adjusting for ART start date, WHO stage 0.81 (0.72–0.92) 0.87 (0.77–0.98) 
Prospective definition of outcome§   
Matched propensity 
score approach† 
start date and WHO disease stage  0.68 (0.60–0.76) 0.72 (0.64–0.81) 
guideline era and WHO disease stage  0.62 (0.55–0.70) 0.75 (0.66–0.85) 
No matching, combined 
Cox model including 
Youth Clinic A & B† 
crude 0.66 (0.59–0.73) 0.68 (0.61–0.75) 
adjusting for start date 0.67 (0.60–0.75) 0.71 (0.64–0.79) 
adjusting for ART start date, WHO stage 0.68 (0.61–0.75) 0.72 (0.64–0.80) 
Adherence club patients only (N=912) 
No matching, combined 
Cox model including 
Youth Clinic A & B‡ 
crude 0.56 (0.32–0.96) 0.83 (0.48–1.45) 
adjusting for start date 0.49 (0.28–0.84) 0.98 (0.56–1.72) 
adjusting for ART start date, WHO stage 0.49 (0.28–0.85) 0.98 (0.56–1.72) 
adjusting for ART start date, WHO stage and age at club start 0.50 (0.29–0.88) 1.00 (0.57–1.77) 
adjusting for ART start date, WHO stage, age at club start and time on 
ART at club start 0.48 (0.28–0.85) 1.07 (0.60–1.90) 
Prospective definition of outcome§   
No matching, combined 
Cox model including 
Youth Clinic A & B‡ 
 
crude 0.50 (0.30–0.85) 0.58 (0.32–1.06) 
adjusting for start date 0.48 (0.28–0.83) 0.61 (0.33–1.12) 
adjusting for ART start date, WHO stage 0.49 (0.29–0.85) 0.60 (0.33–1.10) 
adjusting for ART start date, WHO stage and age at club start 0.49 (0.28–0.84) 0.60 (0.32–1.09) 
adjusting for ART start date, WHO stage, age at club start and time on 
ART at club start 0.48 (0.28–0.82) 0.63 (0.34–1.17) 
†Analyses conducted separately for Youth Clinic A and B.  
‡Analysis of full dataset including Youth Clinic A and B, with general clinics as reference group 
§the first time there is a nine-month gap in care patients are considered lost to follow-up even if they return to care, with the date of last 
visit before the gap in care being the outcome date 
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Adherence club analysis 
At Youth Clinic A, 20% of patients were ever in an adherence club at the clinic, 
compared to 13% at Youth Clinic B and 19% at general clinics. Before joining a 
club, Youth Clinic B patients were on ART for longer (median months: 24.8, IQR: 
15.5–43.6) than those at Youth Clinic A (median: 9.7, IQR: 3.3–20) and general 
clinics (median: 15.3, IQR: 8.6–25.3) (Table 4, Table 11 in Appendix 2).  
 
Youth Clinic A club patients had lower attrition after joining an adherence club 
compared to general clinic patients (HR: 0.56, 95% CI: 0.32–0.96), and this 
protective effect increased after adjustment for ART start date, WHO stage, age 
at club start and time on ART at club start (HR: 0.48, 95% CI: 0.28–0.85). Models 
using the prospective definition of the outcome yielded similar results. Youth 
Clinic B club patients had similar attrition to general clinic club patients in crude 
(HR: 0.83, 95% CI: 0.48–1.45) and fully adjusted models (HR: 1.07, 95% CI: 
0.60–1.90).  
 
Using the prospective definition of the outcome yields similar results for the 
Youth Clinic A analysis, but shows a stronger effect for Youth Clinic B, with a HR 
of 0.58 (95% CI: 0.32–1.06) in the crude model and similar results when 
adjusting for ART start date, WHO stage, age at club start and time on ART at 
club start (HR: 0.63, 95% CI: 0.34–1.17) (Table 6). 
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Quantitative Bias Analysis 
The e-value was 0.6 for the primary Youth Clinic A analysis and 0.66 for Youth 
Clinic B. This means that if there were an unmeasured confounder associated 
with both attrition and Youth Clinic A by a risk ratio of 0.6, then the true clinic-
attrition HR would be 1. For the Youth Clinic A analysis, the upper bound of the 
95% confidence interval would be >1 if there were an unmeasured confounder 
associated with both attrition and Youth Clinic A by a risk ration below 0.72. This 
figure is 0.82 for the Youth Clinic B analysis (Table 13 and Table 14 in Appendix 
2). 
Discussion  
This study has demonstrated lower rates of attrition among HIV-positive youth at 
two youth clinics, compared to youth at general clinics in the same area.  In our 
main propensity score matched analysis, Youth attending Youth Clinic A had 
lower attrition, as did those attending Youth Clinic B to a lesser extent, when 
compared to youth in general clinics. Effect estimates were robust to a variety of 
sensitivity analyses. Youth in adherence clubs at Youth Clinic A were more likely 
to remain in care compared to youth in adherence clubs at general clinics, 
though no such difference was observed between Youth Clinic B and general 
clinic adherence club patients.  
 
Baseline clinic and demographic characteristics were similar across clinic type, 
though general clinics had a slightly higher proportion of patients initiating ART at 
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WHO disease stages 2–4. There were low proportions of males seen at all clinics 
(9%–11%), despite males accounting for 25% of South African youth aged 15–24 
living with HIV in 2018 [1]. Among all age groups in South Africa, ART coverage 
is lower among adult males (58%) compared with adult females (64%)[1], but this 
gap was particularly pronounced among youth in this analysis. Women typically 
have more opportunity to interact with the healthcare system [41,47,69,70], and 
social and cultural barriers [66–68] might make men more resistant to seeking 
care. These factors might be particularly pertinent among young, otherwise 
healthy men, explaining their under-representation in ART care even accounting 
for the presence of male-only clinics in the study area. The similar sex 
distribution between youth and general clinics suggests that the youth clinics 
have not addressed these issues and that these services are missing populations 
in need.  
 
Overall 12-month attrition was 25%, with higher attrition among patients initiating 
with lower baseline WHO disease stage, those on TDF-EFV regimens, and 
higher baseline CD4 counts. Our findings are consistent with other literature, 
suggesting that the benefit of ART may be less apparent to healthier people 
[96,97]. This observation does not hold for those with CD4 counts below 100 
cells/mm3, whose higher 12-month attrition may be explained by higher death 
rates. The higher rates of attrition in those initiating more recently may be an 
artefact of how loss to follow-up is measured: those who initiated earlier have 
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had more chance to return to care. This has also been suggested as an 
explanation for other studies observing increasing attrition over time [146]. As 
ART eligibility has expanded over time, this may partially explain the higher rates 
of attrition among healthier patients in this study, who initiated ART in more 
recent guideline eras.   
 
Both youth clinics showed strong protective effects against attrition compared to 
general clinics.  Youth were similar across clinics at baseline, so it is unsurprising 
that different methods to adjust for measured confounding resulted in similar 
results. Models using the prospective definition of the outcome showed greater 
effect sizes, suggesting more gaps in care among youth in general clinics.   
 
Among adherence club patients, there was a large reduction in attrition in Youth 
Clinic A compared to general clinics. There were few adherence club patients at 
Youth Clinic A under 18 years old, so the observed effect is unlikely to be 
attributable to the club age segregation. Youth Clinic A patients were on ART for 
a shorter period at their first club visit, but adjusting for duration on ART 
strengthened the protective effect. Youth Clinic B had more youth in clubs 
recruited in earlier eras, corresponding to better retention, but after adjusting for 
this there was no difference between retention in Youth Clinic B and general 
clinics. These results should be interpreted with caution because of the small 
number (n=133) ever in clubs at Youth Clinic B. However, the large improvement 
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in outcomes at Youth Clinic A suggest that the model of care that integrates 
family planning within clubs and recruits patients into clubs earlier has added 
benefit above the social support provided by youth clubs.  
 
Data for this analysis were limited to laboratory records and clinical data from 
selected clinics, and may have overestimated attrition due to “silent transfers” 
[83,84], when patients transfer to another clinic without informing the initiating 
clinic. In addition, data quality may differ between clinics, leading to differential 
misclassification of loss to follow-up. A second limitation is the potential for 
unmeasured confounding, stemming from self-selection of youth into the youth 
clinics. However, e-values suggest that strong confounder-exposure and 
confounder-attrition associations would be required to explain away the observed 
effect sizes. It is also possible that unmeasured confounding resulted in an 
under-estimation of the true effect. For example, youth-targeted services, 
including efforts to improve linkage to ART initiation at Youth Clinic A, may have 
selected youth who face more barriers to engagement in care and might not have 
initiated at a general clinic.   
 
HIV-positive youth aged 12–25 years were more likely to be retained in ART care 
in two different youth-targeted clinics compared to general clinics in the same 
area, in matched propensity score analyses. Relative to adherence club patients 
at general clinics, the protective effect was particularly strong among adherence 
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club patients at the youth clinic with a tailored adherence club model, which 
includes integrated family planning. While stand-alone youth clinics are not 
feasible in all settings, these results suggest that multiple approaches to making 
clinics more youth-friendly can contribute to improving retention in this important 
group. 
  




Attrition from care in “Fast-track” Differentiated Model of ART Delivery 
compared to usual care 
Introduction 
Managing stable ART patients in an efficient way can free up clinician time to 
provide care for more unwell patients in South Africa’s overburdened health 
system. Adherence clubs, where patients meet in counselor-led adherence 
support groups to collect their medication, have proven to be an acceptable way 
for stable patients to receive their ART [147,148]. Adherence clubs have been 
successfully implemented in facility and community settings and form part of 
South Africa’s national adherence guidelines[132,135,138,149–152]. Adherence 
clubs reduce the burden on the healthcare system by allowing stable patients to 
collect their medication from a counselor in a group setting, rather than requiring 
individual clinician visits.  
 
Another model of care for stable ART patients that could further reduce health 
system burden are pharmacy-led refill programs[153], also known as fast-track 
refills[154,155]. This is an individual-centered model, where patients pick up their 
medication directly from the pharmacy, without seeing a clinician or counselor as 
they normally would. This minimizes use of clinical and counseling staff’s time, 
thereby reducing cost [156]. However, unlike adherence clubs, pharmacy-led 
refill programs do not function as support groups, which have been associated 
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with improved ART outcomes such as retention in care[157].  
 
While it is hoped that the added convenience of fast-track refill programs will 
decrease attrition from care, no study has compared the outcomes of facility-
based fast-track patients to a comparable group of patients receiving standard 
clinic care [158]. In the context of a facility offering several models of ART 
delivery, we compared attrition from care of patients in a fast-track refill program 




This is a cohort study comparing fast-track patients to ART patients not in any 
differentiated service delivery model, to compare attrition between these two 
groups. 
Population and Setting 
We included adult patients starting ART before October 2017 in a large general 
HIV clinic in Khayelitsha. As of the end of 2018 there were 7601 patients in ART 
care at this clinic. To be eligible for the fast-track refill program, patients were 
required to be on ART for more than six months, have had a suppressed viral 
load in the past six months, not be pregnant and not have tuberculosis.  
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The fast-track program 
In the fast-track refill program, patients collected their ART straight from the 
pharmacist every two months, without a clinician or counselor interaction. Blood 
tests and a clinical visit took place once a year to monitor their health. The clinic 
began implementing the program in October 2015. Patients who met the criteria 
were supposed to be flagged by data clerks, and invited to join the program by a 
clinician at their visit. However, audits have shown that in practice many eligible 
patients were not referred, and continued to receive ART at regular clinical visits.  
Data Source 
Data was supplied by the provincial health data center, which links patient data 
from multiple sources, including routine visit data captured prospectively by the 
facility, demographics, pharmacy pickups, and laboratory data [159].  
Measures 
The exposure was defined as ever joining the fast-track program, compared to 
not joining the fast-track program when eligible. 
 
Patients were matched on official eligibility criteria and time on ART, but other 
patient characteristics may have predicted both fast-track recruitment and patient 
outcomes. Predefined potential confounders included age, sex and clinical 
characteristics at ART initiation. CD4 count (between 180 day before and 30 
days after ART initiation) was used as an indicator of HIV disease progression at 
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ART initiation. Date of ART initiation and time on ART at the beginning of follow-
up time, predictors of both the probability of recruitment into fast-track and 
attrition from care, were also considered as potential confounders. Patients were 
required to be virally suppressed and not have tuberculosis when referred to fast-
track, but it is possible that clinicians were less likely to refer patients with a 
history of tuberculosis or unsuppressed viral loads. These variables were 
operationalized as evidence of prior tuberculosis disease and having a viral load 
result >1000 copies/mL in the past two years. Clinicians may have also been less 
likely to refer patients with other comorbidities to the fast-track program, 
especially if these needed more frequent clinical monitoring. Comorbidities can 
impact patient outcomes, so having any evidence of prior hypertension or 
diabetes were treated as potential confounders. Like patients with comorbidities, 
patients with a history of disengagement from care might have been less likely to 
be referred to fast-track if clinicians perceived them to need more support or 
monitoring. Prior disengagement was defined as not having collected ART for six 
months or more at any point before the start of follow-up time.  
 
The outcome of interest was attrition from care. Attrition included all patients who 
were lost to follow-up or died. While these are distinct outcomes, they are 
combined into one measure as deaths are often not known about at the clinic, 
and so appear as lost to follow-up [160]. Loss to follow-up was defined as not 
receiving ART for six months. This would result in a patient going without ART for 
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at least two months, if the maximum of four months of ART is dispensed, though 
two-month dispensing is more common.   
 
Analysis 
We compared outcomes between patients enrolled in the fast-track program and 
those eligible and never enrolled in fast-track. Those not enrolled typically 
received their medication 5–12 times/year at clinic visits where they saw a 
clinician.  
 
Each fast-track patient was matched 1:1 to patients who were eligible for 
recruitment into fast-track but never enrolled in the program, without 
replacement. Patients were considered eligible for fast-track if they were in clinic 
care, had been on ART for at least six months, had no active TB disease, and 
were not pregnant, on the date of the fast-track patient’s enrolment. Patients in 
ART adherence clubs on the date of the fast-track patient’s enrolment were not 
considered as eligible comparisons, though some matched controls later enrolled 
in adherence clubs. Eligible matches for each fast-track patient varied according 
to their date of fast-track enrolment. From each fast-track patient’s set of eligible 
matches, the selected match was the eligible patient with the closest ART start 
date.  
 
Patients who join the fast-track program but later return to standard of care for 
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any reason (personal choice, becoming ineligible) were not excluded from the 
exposed group, similar to an intention-to-treat analysis. For such patients, the 
disruption to their ART routine might have a negative effect, which should also be 
reflected in the total effect of the intervention.   
 
We compared patient characteristics of fast-track and matched clinic patients. 
Descriptive statistics were presented by exposure group, and 12-month attrition 
was described by baseline characteristics, for those with sufficient follow-up time. 
Multivariable Cox regression analyses were performed to compare fast-track 
attrition to the comparison group. We adjusted for confounders using a 
predefined strategy. Each a priori defined potential confounder was added to the 
model to observe its effect on the crude hazard ratio, then added in order of 
greatest to least effect and retained in the model if it changed the crude hazards 
ratio by more than 10%. 
 
The dataset was closed on 30 September 2018. Follow-up time for each fast-
track patient and their matched controls began on the calendar date of the fast-
track patient’s first fast-track visit. Follow-up time ended on the earliest of (1) date 
of patient’s last ART collection at study clinic before a six-month gap, or (2) 1 
April 2018, to allow time to ascertain whether the patient was lost to follow-up by 
dataset closure. If a patient’s last attended visit was the same as their ART 
initiation date, one day of follow-up was added to prevent them from being 
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excluded from Kaplan-Meier and Cox proportional hazards analyses [74]. 
 
Bias analysis 
Despite matching, confounding could arise if the patients referred to the fast-
track model were different to those eligible who were not offered the option. 
When fast-track recruiting occurs, all eligible patients should be offered the 
option of fast-track, and some were likely not offered the option because of a 
simple oversight. However, it is possible that clinicians chose not to refer patients 
based on unmeasured patient characteristics that also predict attrition, 
introducing unmeasured confounding.  We conducted a bias analysis of 
unmeasured confounding to quantify the effect of a range of associations 
(confounder-exposure and confounder-outcome). The resulting distribution of 
effect sizes will show a range of results that incorporate hypothesized systematic 
and random error.  
 
Potential unmeasured confounders that are known to affect ART retention 
include disclosure of HIV status [161], substance abuse and mental health issues 
[162][87]. In a review of depression and alcohol use and ART adherence in sub-
Saharan Africa, those with depressive symptoms had a 55% lower likelihood of 
good adherence compared to those without. In four alcohol use disorder studies 
in that review, two found large associations between alcohol use disorder and 
adherence (OR 0.30; 95% CI: 0.19–0.73 for good adherence and OR 2.14 ; 95% 
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CI: 1.36–3.37 for poor adherence), while two found null effects [87]. In a more 
recent South African study,  depression (OR 3.46; 95% CI: 1.33, 7.97) and 
alcohol abuse (OR 3.89; 95% CI: 1.70, 8.97) were both strongly associated with 
attrition [108].   
 
Alcohol use disorders and mental health issues are not uncommon in ART 
cohorts, with one study showing that 55% of newly diagnosed HIV patient at 
selected South African clinics had depressive symptoms [163]. In the 
aforementioned systematic review, the pooled prevalence was 31% for 
significant depressive symptoms and 18% for depression. Prevalence of alcohol 
use among study participants ranged from 2.5 to 51% [87].  
 
Based on these estimates, we hypothesized that confounding characteristics 
associated with not being enrolled in fast-track and attrition could lead to 1.5 to 
4.5 times the risk of attrition, which we represented as a triangular distribution 
with a mode of 3 (range: 1.5 – 4.5). The confounder prevalence was specified as 
a triangular distribution with a mode of 40% (range: 30–50%) in the clinic controls 
and a mode of 10% (range: 0–20%) in the fast-track patients.  
 
In addition to the bias analysis, we present the e-value. The e-value is the lowest 
strength of association risk ratio (equal for confounder-exposure and confounder-
outcome) that would explain away an observed effect [90]. We calculated the e-
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value for the observed HR using Stata 14 [91].  
 
Results  
Since October 2015, 7950 patients with an ART initiation date prior to 1 October 
2017 received ART care at the clinic. Of these, 6759 patients were not enrolled in 
fast-track during the study period, and 1138 patients were enrolled before 1 April 
2018.  
 
Fast-track patients and matched controls had similar characteristics at ART 
initiation. In both groups 42% initiated ART between August 2011 and December 
2015, with a median CD4 count of 244 cells/mm3 (IQR: 151–353) for fast-track 
patients and 248 (IQR :138–347) for controls. Both groups were 29% male 
(Table 7). 
 
Patients were also similar in terms of age (overall median: 38, IQR: 32–45) and 
time on ART (overall median: 40.4, IQR: 21.6–68.7) at the fast-track patient’s first 
fast-track visit. Fast-track patients were less likely to have had prior tuberculosis 
(23% vs 28%), prior diabetes (1% vs 7%) and prior hypertension (12% vs 27%), 
compared to controls. 
 
In a crude analysis of the matched cohort, 12 months after fast-track enrolment, 
fast-track patients were less likely to be lost from care at the clinic (5% vs 14%) 
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and less likely to have a viral load result (64% vs 77%) compared to controls. 
Among those with results available, fast-track patients were more likely to have a 
suppressed viral load (96% vs 92%) though overall only 64% of fast-track 
patients had a suppressed viral load compared to 74% of the controls (Table 7). 
Among the 294 fast-track patients with incomplete 12-month viral loads, 268 
(91.2%) were still in care at 12 months, compared to 65.9% (116/176) control 
patients with incomplete viral loads. Of the remaining 268 fast-track patients who 
were retained at 12 months with no viral load results, 193 (72.0%) had a 
subsequent (late) viral load result, of whom 181 (93.8%) were virally suppressed. 
Follow-up time was insufficient to report viral load completion in the second year 
of the fast-track program.   
 
After fast-track enrolment, 11% of fast-track pats joined an adherence club, 
compared to 19% of controls. Fast-track patients were less likely to develop TB 
disease (1% vs 5%) or die (0.4% vs 0.6%).  
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Table 7 Demographics, clinical characteristics and outcomes of fast-track patients 
and matched controls 
 Fast-track patients 
N (%)  
Matched controls 
N (%) 
N 1138 1138 
ART initiation period by CD4 eligibility criteria (cells/mm3):  
 Guidelines CD4<200 (before August 2011) 331 (29%) 332 (29%) 
 Guidelines CD4<350 (Aug 2011– Dec 2015) 478 (42%) 477 (42%) 
 Guidelines CD4<500 (1 Jan 2015– 31 Aug 2016) 275 (24%) 275 (24%) 
 After Universal Test and Treat (1 Sept 2016) 54 (5%) 54 (5%) 
CD4 Count at ART initiation (cells/mm3)   
  median (IQR) 244 (151–353) 248 (138–347) 
  CD4 count missing 237 (21%) 249 (22%) 
Male 331 (29%) 345 (29%) 
Characteristics at fast-track enrolment*  
  median age (IQR) 37.4 (32.1–43.5) 39.4 (32.0–47.1) 
  median months on ART(IQR) 40.4 (21.6–68.8) 40.4 (21.6–68.6) 
  Any VL >1000 copies/ml in two years prior 85 (7%) 107 (9%) 
  Missing viral load results in two years prior 5 (0%) 0 (0%) 
  Last viral load suppressed 1119 (99%) 1138 (100%) 
  Prior TB 265 (23%) 321 (28%) 
  Prior diabetes 15 (1%) 82 (7%) 
  Prior hypertension 139 (12%) 306 (27%) 
  Prior gap in care of >6 months 42 (4%) 70 (6%) 
Outcomes: 12-month outcomes after fast-track enrolment*  
  N (with fast-track enrolment before 1 July 2017) 818 818 
  12 month attrition from care 39 (5%) 118 (14%) 
  Viral load complete 524 (64%) 642 (78%) 
  Viral load suppressed (of complete) 502 (96%) 604 (94%) 
  Viral load suppressed (of total) 502 (61%) 604 (74%) 
Other outcomes after fast-track enrolment*  
  Joined adherence club 127 (11%) 217 (19%) 
  TB disease 16 (1%) 59 (5%) 
  Died 4 (0%) 8 (1%) 
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Overall, among those enrolled in fast-track before 1 July 2017 and their matched 
controls, 12-month attrition from care was 10%. Attrition from care was 
associated with more recent ART initiation era and higher baseline CD4 count 
(15% among CD4>500 cells/mm3, compared to 10% among CD4<200 
cells/mm3). Being younger at fast-track enrolment was associated with higher 
attrition (17% among those under 30 years old compared to 7% among those 30-
40 years old and 9% among those over 40). Being on ART for longer at 
enrolment was associated with lower attrition (8% among those on ART for over 
three years compared to 13% among those on ART for less than two years). 
Prior TB was associated with a slightly higher rate of attrition (11% vs 9%) than 
no prior TB (Table 8).  
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Table 8  12-month retention in care by patient demographic and clinical 
characteristics, among those enrolled in fast-track before 1 July 2017 and 
matched controls 
 N % attrition at   12 months 
Total 1636 10% 
ART initiation period by CD4 eligibility criteria (cells/mm3): 
 Guidelines CD4<200 (before August 2011) 529 8% 
 Guidelines CD4<350 (Aug 2011– Dec 2015) 755 9% 
 Guidelines CD4<500 (1 Jan 2015– 31 Aug 2016) 330 12% 
 After Universal Test and Treat (1 Sept 2016) 22 27% 
CD4 Count at ART initiation (cells/mm3)  
  <200 508 10% 
  200–350  468 8% 
  350–500 189 12% 
  >500 106 15% 
 CD4 count missing 365 8% 
Sex   
  Male 479 8% 
  Female 1157 10% 
Characteristics at fast-track enrolment* 
Age   
  18–29 years 250 17% 
  30–40 years 674 7% 
  40< years 712 9% 
Months on ART  
 <24 months 448 13% 
 24–36 months 258 11% 
 36< months 930 8% 
Any VL >1000copies/ml in two years prior 
  Yes 148 9% 
  No 1486 10% 
  no VLs in two years prior  2 0% 
Prior TB   
  Yes 438 11% 
  No 1198 9% 
Prior diabetes   
  Yes 72 11% 
  No 1564 10% 
Prior hypertension   
  Yes 301 9% 
  No 1335 10% 
Prior gap in care of > 6 months   
  Yes 96 31% 
  No 1540 8% 
*for clinic patients enrolment refers to the fast-track start date of their fast-track match 




Kaplan-Meier failure estimates showed a lower attrition over time in the fast-track 
patients compared to clinic controls (Figure 5). The Cox regression analysis 
reflected 291 events among the 2276 observations. No covariates were retained 
in the final model. The hazards ratio was 0.40 (95% CI: 0.31–0.51), reflecting a 
large protective effect of fast-track enrolment compared to being eligible but not 
enrolled (as reflected by 5% vs. 14% 12-month attrition in Table 7).   
  









0 .5 1 1.5 2 2.5
years
95% CI 95% CI
Clinic patients Fast-track
Attrition by exposure group
Kaplan-Meier failure estimates
    
 
70 
Bias analysis of uncontrolled confounding.  
The Cox regression was rerun 100 000 times on the matched dataset, adjusting 
for a simulated confounder, generated using the hypothesized confounder-
attrition risk ratio (triangular distribution with mode 3 and range: 1.5 – 4.5), 
confounder prevalence in the matched controls (mode 40%, range: 30–50%) and 
confounder prevalence in the fast-track patients (mode 10%, range: 0–20%). The 
resulting hazard ratio adjusted for random and systematic error is 0.60 (95% 
interval: 0.42–0.89) (Figure 14 in Appendix 3). 
 
The e-value was 3.16, meaning that in order for the observed effect to be 
explained away by confounding, a confounder would have to lead to a 3.16 times 
larger risk of both attrition and not being enrolled in fast-track (or 0.32 times the 
chance of being enrolled in fast-track). Figure 6 reflects the full range of 
confounder-fast-track and confounder-attrition associations with the potential to 
nullify the observed effect.   




Figure 6  Range of fast-track-confounder and attrition-confounder relationships 
that would explain away the observed effect of fast-track of attrition 
 
The upper bound of the confidence interval around the fast-track-attrition hazards 
ratio would be 1 if there was a confounder associated with 2.5 times larger risk of 
both attrition and not being enrolled in fast-track. In other words, if the risk ratios 
associating the confounder with non-enrolment and attrition are both less than 
2.5, then the exposure-outcome hazards ratio confidence interval does not 
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We matched fast-track patients to a demographically similar group of patients 
who were not recruited to the fast-track program, but were eligible for recruitment 
at the same time as the fast-track patients, in order to compare attrition between 
these two groups. The matched cohort had similar characteristics at ART 
initiation, and similar time on ART, with the only notable difference being a larger 
proportion with diabetes and hypertension. Fast-track patients were less likely to 
have demonstrated viral suppression after 12 months of follow-up, though those 
with viral load results available had 96% suppression rates. Fast-track patients 
experienced substantially less attrition (HR: 0.4; 95% CI: 0.31–0.51) over the 
follow-up period.  
 
High retention in the fast-track group demonstrates that stable patients can 
remain in ART care with minimal counselling and clinician interactions. This is in 
line with recent literature showing non-inferior outcomes among patients given 
six months of ART at a time [164–166]. The lower attrition among fast-track 
patients compared to fast-track-eligible but not enrolled is unlikely to be entirely 
due to unmeasured confounding introduced by clinicians differentially referring 
patients into the program. The quantitative bias analysis assumed strong 
associations between unmeasured confounders and fast-track referrals, and 
unmeasured confounders and attrition. Taking into account these parameters, 
the bias-adjusted HR was 0.6 (95% interval: 0.42–0.89).  
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A potential concern is the lower rates of viral load completion among fast-track 
patients. Viral load testing is an important monitoring tool for the management of 
ART patients, and poor viral completion despite high retention suggests that this 
was neglected in the fast-track program. In the absence of regular clinician 
contact, systems need to be put in place to ensure bloods are drawn in time for 
clinical visits, and that these clinical visits take place annually. While the high 
viral suppression rates among those who did have blood results is reassuring, 
this is a key issue to address in the implementation of differentiated service 
delivery models that reduce clinician contact.  
 
As HIV cohorts have aged, an increasing proportion of people on ART have other 
comorbidities[167]. In this study, a larger proportion of matched controls had 
diabetes than fast-track patients (7% vs. 1%) and hypertension (27% vs. 12%). 
Clinicians may be less likely to refer patients with comorbidities to fast-track 
programs because of a need for more frequent clinician monitoring. However, 
hypertension and diabetes were not associated with 12 month attrition, nor did 
they substantively change the association between fast-track enrolment and 
attrition in the Cox regression analysis. Few differentiated service models actively 
incorporate comorbidity management, and for many it is an exclusion criteria 
[155]. This runs the risk of fragmenting patient care, and vertical ART dispensing 
programs miss the opportunity to simultaneously dispense other chronic 
medication [21]. While not addressed in this paper, future research should 
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explore the extent to which differentiated services can integrate the dispensing of 
chronic medication, increasing convenience to existing patients, and expanding 
the eligibility criteria of such models.  
 
This study is limited as it only reflects a fast-track model at a single clinic, and the 
relative strengths of different systems in other clinics may vary. In addition, this is 
an evolving program. After the study period, responsibility for fast-track patients 
shifted from the pharmacists to counselors, who managed the distribution of 
drugs, and are better placed to advise patients about blood-draws and clinical 
visit schedules. Studies of longer term outcomes will need to take the changing 
intervention into account. The data is limited to what is captured in routine 
services and available in the provincial health data center. Patients who 
transferred to care in other provinces would reflect as lost to care in this analysis, 
but this is unlikely to differ between exposure groups.  
 
In the context of an experienced ART cohort, this study has demonstrated lower 
attrition and high viral suppression among patients enrolled in a fast-track ART 
dispensing model compared to eligible matched controls.  





This dissertation has assessed the effect of differentiated service delivery on 
attrition in three different populations on ART: men, youth, and stable patients. 
The first study compared attrition from care between males attending two male 
clinics and those attending general primary healthcare clinics. Patients from male 
clinics were younger than males from general clinics and had higher median CD4 
counts at ART initiation. Patients initiating ART at male clinics had lower attrition, 
but in separate analyses, only the more established male clinic showed a 
protective effect.  The second study examined attrition from care among youth 
(aged 12–25) on ART in two youth clinics compared to those attending general 
primary healthcare clinic. The distribution of age, sex, and CD4 count at ART 
initiation was similar across youth and general clinics. We observed a protective 
effect against attrition for among patients at Youth Clinic A and Youth Clinic B 
compared to youth at general clinics. Among adherence club patients, Youth 
Clinic A club patients had lower attrition after joining an adherence club 
compared to general clinic patients while Youth Clinic B showed no effect. The 
third study matched patients in a pharmacy-led fast-track ART refill program to 
stable, otherwise healthy, patients who were eligible for the fast-track program at 
the same point in time but did not join. Fast-track enrolment was highly protective 
against attrition.  
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The use of matched comparison groups is a strength of these studies, as 
selection of unbiased comparison groups for observational studies of 
differentiated models of care is often challenging, and most studies report results 
without comparison groups [158]. Results were generally robust to sensitivity 
analyses using other methods of adjustment for confounding, and quantitative 
bias analyses showed that unmeasured confounding was unlikely to explain 
away all of the protective effects.   These results provide evidence for male 
clinics, youth clinics, and fast-track models as models of ART delivery that 
reduce attrition from care.   
 
However, no single model can address all the issues that lead to attrition from 
care. Even in a relatively well-resourced setting, both youth clinics and both male 
clinics had more than 20% attrition 12 months after ART initiation. This reflects 
the myriad challenges that might lead patients to reach a “tipping point” for 
disengagement from care [168]. Over a lifetime on ART, patients will have 
changing needs for peer support, clinical management, convenience, and 
integration of other services, such as postnatal care [27,169,170], or family clubs 
for children and caregivers on ART [171]. Qualitative research of HIV-positive 
people on ART reflects this diverse set of needs: for example, peer support is 
appreciated by newly diagnosed patients [172], youth [26,173], adherence club 
members [147] and postnatal mothers [169], but stable patients also value 
convenience of less frequent ART pick-ups [174] or less waiting time [175,176]. 
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The relative successes of the interventions described in this dissertation should 
be seen as potential components of a package of complementary interventions. 
 
The components of differentiated service delivery offered at a particular facility 
needs to take into account program context, patients’ clinical and socio-
demographic characteristics, and resources [22,177].  Relative costs and 
benefits of different models vary by context. For example, community–based 
models will have greater impact if physical space in facilities is limited, and in 
rural areas where patients have far to travel [178–180]. Provider costs also vary 
a lot by region, largely because of varying costs of healthcare staff  [181]. 
Another consideration is the capacity of the system to manage and monitor 
multiple models, as each new model adds complexity to processes such as 
patient flow, data, and pharmacy processes [182,183]. It may also be challenging 
to correctly allocate patients to different services, especially as their clinical and 
social needs evolve [184,185]. However, if differentiated service delivery is 
viewed as more of a ‘patient-centered approach’ and less as distinct models, 
there is potential for synergy between services catering to different patient 
groups [186].  
 
The overlaps between the interventions described in this dissertation highlight 
some potential synergies. Youth and males are harder to attract and retain in 
ART care, and in the second study, young males were particularly under-
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represented in all clinics compared to their female counterparts. This could be 
addressed, where resources allow, by creating a male-friendly environment for 
youth, by for example having a male counsellor in a youth clinic. The peer-
support component of adherence clubs may be enhanced by having youth-
specific peer support. The success of including family planning in Youth Clinic 
A’s youth clubs adds to evidence that integrating services may also enhance 
convenience and retention in other populations, such as non-communicable 
diseases and HIV treatment among aging populations [187]. Similarly, the 
convenience of the fast-track model may be particularly appealing to HIV-
positive, healthy youth [173] and men [175]. Reducing health system contact of 
stable patients, such as those in the fast-track program, allows healthcare 
providers more time to address the needs of patients with more complex clinical 
or social needs. Reduction in long term costs of poor health outcomes may offset 
costs of more intensive interventions [154], especially among youth, with many 
years of ART ahead of them [125]. 
 
Finally, when evaluating ART programs, future research should consider the 
impact of different ways of measuring attrition. Both of the first two studies 
showed stronger effects when using a prospective definition of attrition. This 
suggests that male and youth clinics may be particularly protective against 
shorter disengagements from care, which is a growing concern with increasing 
ART duration [28,98,99]. Moreover, all analyses in this dissertation began follow-
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up time for patients at clearly defined time points – date of first ART initiation, 
adherence club enrolment, or fast-track enrolment – and measured attrition as a 
single binary outcome. However, as ART cohorts age, a larger proportion of 
patients have gaps in care, and patients may restart ART multiple times. For 
example, in the Western Cape province in South Africa, among patients 
presenting with advanced HIV (CD4 counts <50 cells/mm3), the proportion who 
had previously been on ART increased every year from 2008 to 2017. Among 
these ART-experienced patients, the proportion with gaps in care since ART 
initiation increased over time [65]. Medication possession ratios [188] or the 
number of missed visits in a time period [189] might be more nuanced measures 
of engagement, reflecting the nature of lifelong ART where patients cycle in and 
out of care as different challenges arise [28].  
 
While stand-alone youth and male clinics are not feasible in all settings, and fast-
track models may not be suited to all patients,  the results presented in this 
dissertation suggest that multiple approaches tailored to specific populations’ 
needs can contribute to improving retention. 
 
    
 
80 
Appendix 1: Chapter 2 Supplementary material 
Figure 7 shows the distribution of selected parameters used in the quantitative 
bias analysis.  
 
Figure 7 Distribution of simulated values of risk ratio (confounder-12 month 
attrition), and prevalence of the confounder in the male and general clinics 
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Figure 8 shows the HR estimate from the main analysis, as well as the adjusted 
HR from the quantitative bias analysis (see also Table 9) . The black line shows 
a distribution of simulated HR values after adjusting for the hypothesized 
confounding using the distribution of parameters in Figure 7. The blue line shows 
the same simulated values, with random error added, approximating the total 
error. Incorporating total error, the median adjusted HR is 0.86 (95% interval: 
0.71–1.05).   
  



















Figure 8 Distribution of estimated hazards ratio (per analysis above), the hazards 
ratio including simulated systematic error, and hazards ratio distribution 
incorporating random and systematic error 
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Table 9 Hazards ratios incorporating systematic and random error 
Description HR  
 
(95% Interval) 
Primary analysis using propensity-score 




HR adjusted for systematic error 0.86 
 
(0.83–0.92) 
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Appendix 2: Extra tables and figures 
 
 
Figure 9 Distribution of propensity scores by clinic type before matching 
 
Figure 9 shows a reasonable separation between general and male clinics, with 
many general clinic attendees having a low predicted probability of attending a 
male clinic. However, because of a larger sample of general clinic attendees, 
there was sufficient “common support” [190]: there were enough general clinic 
patients with a similar range of propensity scores to male clinic patients to allow 
for close matching.   
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Men in the male clinics and comparison groups were younger and healthier.  
 
Figure 10 Comparison of characteristics of male clinic patients, and matched and 
unmatched general  clinic patients  
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The plot of the residuals over time (Figure 11) shows potential violations of the 
assumption of proportional hazards only after 30 months, where data is scarcer.  
 
 
Figure 11 Plot of Schoenfeld residuals over time  
  




Table 10 Summary of Cox regression results with e-values and goodness of fit 
test results 












Primary analysis using propensity-
score matched cohort, no covariates 
included 
0.83 
(0.69–1.00) 0.66 (1) 0.8764 
1 Include only Male Clinic 1 and 
respective matched controls 
0.83 
(0.65–1.07) 
0.66 (1) 0.5550 
2 Include only Male Clinic 2 and 




3 Prospective definition of outcome 0.71 
(0.60–0.85) 
0.54 (0.68) 0.9532 
4 Not considered attrition if patient had 
viral load within 1 year 
0.82 
(0.68–0.99) 0.64 (0.93) 0.9167 
 
 




Figure 12 Kaplan-Meier curves of Male Clinic 1 and Male Clinic 2 attrition 
compared to respective matched controls 
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Appendix 2: Chapter 3 Supplementary material 
 
Figure 13 Distribution of propensity scores by clinic type   





Table 11 Baseline characteristics of ART patients who ever joined an adherence club before the age of 26, by clinic type 
 Youth Clinic A Youth Clinic B General clinics 
N 242 133 537 
Era of ART initiation    
  Eligibility CD4<200 (before August 2011) 2% 12% 3% 
  Eligibility CD4<350 (Aug 2011–31 Dec 2014) 19% 56% 29% 
  Eligibility <500(1 Jan 2015 – 31 Aug 2016) 47% 22% 52% 
  All eligible (1 Sept 2016) 32% 11% 15% 
Age at first club visit    
  12–17 years 3% 4% 3% 
  18–25 years 97% 96% 97% 
Median age (years) (IQR) 22 (20.7–23.8) 22.9 (21.4–24.5) 23.8 (22–24.9) 
Sex    
  Male 10% 7% 11% 
WHO stage at ART initiation     
  Stage 1 80% 74% 75% 
  Stage 2 11% 13% 14% 
  Stage 3 3% 9% 4% 
  Stage 4 0% 1% 1% 
  Stage 2–4 14% 23% 19% 
 Stage missing 6% 4% 6% 
CD4 Count at ART initiation (cells/mm3)     
 <200 11% 13% 14% 
 200–349  31% 36% 34% 
 350–500 31% 29% 29% 
  >500 21% 12% 17% 
  Missing 6% 10% 7% 
Median CD4 count (IQR) 368 (287–477) 335.5 (229.5–456.5) 344.5 (250–459) 
  EFV-free regimens 1% 8% 2% 
  TDF-free regimens 1% 4% 1% 
  Missing regimen information 5% 3% 1% 
Median months in club (before age 26) 11.7 (4.6–21.1) 10.1 (1.8–20.5) 16.7 (6.3–25.8) 
Median months on ART before club 9.7 (3.3–20) 24.8 (15.5–43.6) 15.3 (8.6–25.3) 





Table 12  Attrition by baseline characteristics and clinic type 
 6-month attrition† 12-month attrition‡ 









 N=1225 N=1129 N=2803 N=1039 N=978 N=2523 
Total 15% 17% 21% 22% 24% 27% 
Sex       
  Male 15% 16% 19% 18% 23% 26% 
  Female 15% 17% 21% 22% 24% 28% 
Era of ART initiation (by CD4 count eligibility criteria)    
  <200 (before August 2011) 7% 11% 13% 18% 18% 17% 
  <350 (Aug 2011–31 Dec 2014) 13% 14% 18% 20% 20% 24% 
  <500 (1 Jan 2015 – 31 Aug 2016) 16% 16% 21% 23% 26% 29% 
  All eligible (After 1 Sept 2016) 23% 28% 30% 28% 35% 38% 
Age       
  12–17 years 13% 16% 18% 19% 21% 24% 
  18–25 years 15% 17% 22% 22% 24% 28% 
WHO stage at initiation     
  Stage 1 16% 18% 21% 23% 26% 28% 
  Stage 2 8% 10% 17% 11% 12% 23% 
  Stage 3 15% 10% 15% 20% 16% 20% 
  Stage 4 25% 23% 24% 43% 26% 28% 
  Stage 2–4 10% 12% 17% 14% 16% 22% 
Stage missing 26% 23% 32% 34% 32% 38% 
Baseline CD4 Count      
 <200 13% 13% 18% 18% 21% 23% 
 200–350  13% 13% 20% 21% 17% 26% 
 350–500 17% 20% 23% 22% 29% 31% 
 >500 21% 23% 24% 29% 26% 32% 
 CD4 count missing 17% 21% 20% 23% 40% 27% 
ART Regimen at initiation     
 EFV-free regimens 4% 11% 16% 10% 15% 18% 
 TDF-free regimens 10% 11% 13% 17% 17% 18% 
 TDF-EFV regimens 16% 18% 22% 22% 25% 28% 





 missing regimen information 28% 17% 35% 36% 21% 47% 
Ever in adherence club at clinic 1% 1% 0% 3% 2% 2% 
Never in adherence club at clinic 19% 19% 27% 27% 28% 35% 
† 6-month retention is only presented for those who initiate ART more than nine months before dataset closure 
‡12-month retention is only presented for those who initiate ART more than 15 months before dataset closure 
 
  





Table 13 Youth Clinic A: summary of Cox regression results, e-values and goodness of fit test results 
Method Variables adjusted for/included in propensity 
score model 
HR of risk of 
attrition in youth 
clinic vs. general 











Full cohort Analyses  
Matched propensity 
score approach† 
start date and WHO disease stage  0.81 (0.70–0.93) 4367 (833) 0.03 0.63 (0.77) 
guideline era and WHO disease stage  0.74 (0.65–0.85) 4290 (862) 0.02 0.57 (0.67) 
No matching, 
combined Cox model 
including Youth Clinic 
A & B‡ 
crude 0.78 (0.69–0.88) 8896 (1759) 0.04 0.60 (0.71) 
adjusting for start date 0.80 (0.71–0.91) 8896 (1759) 0.16 0.63 (0.74) 
adjusting for ART start date, WHO stage 0.81 (0.72–0.92) 8896 (1759) 0.43 0.64 (0.76) 
Prospective definition of outcome§    
Matched propensity 
score approach† 
start date and WHO disease stage  0.68 (0.60–0.76) 3770 (1091) 0.55 0.51 (0.59) 
guideline era and WHO disease stage  0.62 (0.55–0.70) 3689 (1122) 0.35 0.47 (0.53) 
No matching, 
combined Cox model 
including Youth Clinic 
A & B† 
crude 0.66 (0.59–0.73) 7708 (2312) 0.96 0.50 (0.56) 
adjusting for start date 0.67 (0.60–0.75) 7708 (2312) 0.88 0.51 (0.57) 
adjusting for ART start date, WHO stage 0.68 (0.61–0.75) 7708 (2312) 0.6 0.51 (0.58) 
Adherence club patients only   
No matching, 
combined Cox model 
including Youth Clinic 
A & B‡ 
crude 0.56 (0.32–0.96) 970.57 (95) 0.55 0.42 (0.84) 
adjusting for start date 0.49 (0.28–0.84) 970.57 (95) 0.15 0.37 (0.67) 
adjusting for ART start date, WHO stage 0.49 (0.28–0.85) 970.57 (95) 0.31 0.38 (0.67) 
adjusting for ART start date, WHO stage and 
age at club start 
0.50 (0.29–0.88) 970.57 (95) 0.26 0.38 (0.71) 
adjusting for ART start date, WHO stage, age 
at club start and time on ART at club start 
0.48 (0.28–0.85) 970.57 (95) 0.19 0.37 (0.67) 
Prospective definition of outcome§  
No matching, 
combined Cox model 
including Youth Clinic 
A & B‡ 
 
crude 0.50 (0.30–0.85) 895.46 (99) 0.65 0.38 (0.68) 
adjusting for start date 0.48 (0.28–0.83) 895.46 (99) 0.02 0.37 (0.65) 
adjusting for ART start date, WHO stage 0.49 (0.29–0.85) 895.46 (99) 0.73 0.38 (0.67) 
adjusting for ART start date, WHO stage and 
age at club start 
0.49 (0.28–0.84) 895.46 (99) 0.7 0.38 (0.66) 





 adjusting for ART start date, WHO stage, age 
at club start and time on ART at club start 
0.48 (0.28–0.82) 895.46 (99) 0.73 0.37 (0.64) 
†Analyses conducted separately for Youth Clinic A and B.  
‡Analysis of full dataset including Youth Clinic A and B, with general clinics as reference group 
§the first time there is a nine-month gap in care patients are considered lost to follow-up even if they return to care, with the date of last 
visit before the gap in care being the outcome date 
  





Table 14 Youth Clinic B: summary of Cox regression results, e-values and goodness of fit test results 
Method Variables adjusted for/included in propensity 
score model 
HR of risk of 
attrition in youth 
clinic vs. general 












Full cohort Analyses  
Matched propensity 
score approach† 
start date and WHO disease stage  0.85 (0.74–0.98) 4341 (804) 0.16 0.68 (0.88) 
guideline era and WHO disease stage  0.90 (0.78–1.03) 4388 (787) 0.17 0.73 (1) 
No matching, 
combined Cox model 
including Youth Clinic 
A & B‡ 
crude 0.80 (0.71–0.90) 8896 (1759) 0.04 0.62 (0.73) 
adjusting for start date 0.86 (0.76–0.97) 8896 (1759) 0.16 0.69 (0.86) 
adjusting for ART start date, WHO stage 0.87 (0.77–0.98) 8896 (1759) 0.43 0.70 (0.89) 
Prospective definition of outcome§    
Matched propensity 
score approach† 
start date and WHO disease stage  0.72 (0.64–0.81) 3796 (1064) 0.7 0.55 (0.63) 
guideline era and WHO disease stage  0.75 (0.66–0.85) 3824 (1044) 0.89 0.58 (0.67) 
No matching, 
combined Cox model 
including Youth Clinic 
A & B† 
crude 0.68 (0.61–0.75) 7708 (2312) 0.96 0.51 (0.58) 
adjusting for start date 0.71 (0.64–0.79) 7708 (2312) 0.88 0.54 (0.61) 
adjusting for ART start date, WHO stage 0.72 (0.64–0.80) 7708 (2312) 0.6 0.55 (0.62) 
Adherence club patients only   
No matching, 
combined Cox model 
including Youth Clinic 
A & B‡ 
crude 0.83 (0.48–1.45) 970.57 (95) 0.55 0.66 (1.00) 
adjusting for start date 0.98 (0.56–1.72) 970.57 (95) 0.15 0.88 (1.00) 
adjusting for ART start date, WHO stage 0.98 (0.56–1.72) 970.57 (95) 0.31 0.88 (1.00) 
adjusting for ART start date, WHO stage and 
age at club start 
1.00 (0.57–1.77) 970.57 (95) 0.26 0.96 (1.00) 
adjusting for ART start date, WHO stage, age at 
club start and time on ART at club start 
1.07 (0.60–1.90) 970.57 (95) 0.19 0.78 (1.00) 
Prospective definition of outcome§  
No matching, 
combined Cox model 
including Youth Clinic 
A & B‡ 
 
crude 0.58 (0.32–1.06) 895.46 (99) 0.65 0.44 (1.00) 
adjusting for start date 0.61 (0.33–1.12) 895.46 (99) 0.02 0.46 (1.00) 
adjusting for ART start date, WHO stage 0.60 (0.33–1.10) 895.46 (99) 0.73 0.46 (1.00) 
adjusting for ART start date, WHO stage and 
age at club start 
0.60 (0.32–1.09) 895.46 (99) 0.7 0.45 (1.00) 





 adjusting for ART start date, WHO stage, age at 
club start and time on ART at club start 
0.63 (0.34–1.17) 895.46 (99) 0.73 0.48 (1.00) 
†Analyses conducted separately for Youth Clinic A and B.  
‡Analysis of full dataset including Youth Clinic A and B, with general clinics as reference group 
§the first time there is a nine-month gap in care patients are considered lost to follow-up even if they return to care, with the date of last 
visit before the gap in care being the outcome date 
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